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1. ABSTRACT 
 
The prevalence rate of Autism Spectrum Disorder (ASD) has reached over 1% world-wide prompting governments, 
health providers and schools to develop programs and policies to address this challenging disorder. Here, we review the cause(s), as 
well as environmental factors, genetic mutations, and neural pathways that are implicated in ASD and criteria that are commonly 
used for its diagnosis and future clinical genetic testing that can aid in the diagnosis of this disorder. Finally, we provide practical 
steps that can be used to reduce the incidence and severity of ASD, as well as prognosis and treatment of autism. 
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2. INTRODUCTION 
 
Autism Spectrum Disorder (ASDs; MIM 209850) is one of the most common and challenging neurodevelopmental 
disorders in children. ASD is characterized by deficits in communication and social interaction, as well as the presence of repetitive 
and restrictive behaviors. ASD often manifests with a wide range of comorbidities including morphological (macrocephaly), 
physiological (gastrointestinal and/or sleep problems) and psychiatric (anxiety) conditions (1). The most common proposed causes 
of ASD are physiological and metabolic disorders, involving immunity, oxidative stress and mitochondrial dysfunction (2). There is 
no pharmacological cure to ASD; however, early diagnosis (12 to 18 months) and intervention coupled with remedial services is 
highly beneficial to patients (3). 
 
The number of individuals diagnosed with ASD has increased dramatically over the past 40 years, affecting roughly 1:60 
children (3). This increase in diagnosis has led to large-scale research initiatives, awareness campaigns, and the need for 
government support. Currently, ASD is diagnosed clinically based on the severity of a heterogeneous list of social, communicative, 
and behavioral deficits; however, there is no universal standardized assessment for ASD. The broad clinical diagnosis provides 
practical means to obtain intervention and services, but may adversely impact research, prevalence rates and public understanding 
of the disorder. This article aims to provide the reader with a succinct understanding of what a current diagnosis of ASD entails, the 
multidisciplinary research (environmental and genetic) surrounding its causes, as well as, recommendations for future diagnostic 
methods to improve prognosis. 
 
3. PREVALENCE  
 
The prevalence of ASD and the marked increase of diagnosis have been a cause for debate. Roughly, one in 60 
individuals are estimated to suffer from deficits falling under ASD. As a result, this is triggering a tremendous strain on the 
education, health and social service sectors (4). This incidence number appears to be consistent globally and across ethnic and 
socioeconomic groups (3). A pressing question in recent literature addresses whether the prevalence of autism between the 1970s 
and the 1990s was underdiagnosed, or if there is a true recent increase in individuals with ASD. While it is hard to quantify the level 
of influx in individuals with ASD phenotypes, several known factors have been attributed to the increase in clinical diagnosis 
(Table 1). These factors include: (a) the broadening of diagnostic criteria, (b) the increased efficiency over time in case 
identification methods used in surveys, (c) changes in diagnostic practices, and (d) the diagnostic substitution (or switching) when 
some diagnostic categories become increasingly familiar to health professionals and/or when access to better services are insured by 
using a new diagnostic category (5). Studies analyzing prevalence are vital in assisting providers and governments in their service 
planning; however, precaution needs to be taken when linking causation with prevalence due to the heterogeneous nature of 
diagnostic criteria. Interestingly, in a recent US study (6) an association between geographical location and significantly decreased 
ASD odds suggests the influence of social and environmental factors affecting etiology or diagnosis. 
 
Outside High-Income Countries (HICs), public health investigation into the prevalence of ASD, and initiatives concerning 
the impact of ASD remain poorly implemented. To date, 86.5% of all cases of ASD have been reported in HICs representing only 
20% of the world population. Insufficient population-based studies have been conducted in Low to Medium Income Countries 
(LMICs), which may well underrepresent the impact of ASD. There are also difficulties in measuring the prevalence of ASD, 
stemming from population awareness, selection of studies and diagnostic capabilities, as well as cross-cultural appropriateness and 
comparability of ASD screening, measurement, and epidemiological data. The uneven rates of diagnosis have also led to variations 
in ASD prevalence by race and ethnicity including the MENA and Gulf regions as stated in the 2016 WISH Report on autism (7). 
Therefore, the knowledge gap between evidence and action in the care of ASD in LMICs has remained considerably wide. 
 
4. RESEARCH INTO CAUSATION 
 
4.1. Comorbidities  
In searching for a cure to ASD, the emphasis is that it is not a single medical condition, but a heterogeneous array of 
phenotypes. The co-occurrence of two or more disorders in the same individual was noticed in ASD. Comorbid conditions such as 
multiple psychiatric disorders anxiety, depression, attention deficit/hyperactivity disorder (AD/HD), epilepsy, gastrointestinal 
symptoms/problems, sleep disorders, learning disability, obsessive compulsive disorder (OCD), intellectual disability, sensory 
problems and Immune Disorders were found in ASDs, (1, 3, 8-12)  
 
ASD can be part of known genetic syndromes. ASD was also found to overlap with other genetic disorders such as Rett 
syndrome (RTT, MIM 312750), Angelman syndrome (AS; MIM 105830), Adenylosuccinate Lyase deficiency (ADSLD; MIM 
103050), Tuberous Sclerosis, Tourette’s syndrome (TS; MIM 137580), Fragile X syndrome (FXS; MIM 300624), Timothy 
syndrome (TS; MIM 601005), PTEN-Related Disorders, Neurofibromatosis type 1 (NF1; MIM 162200), Down syndrome (DS; 
MIM 190685), Smith–Lemli–Opitz syndrome (SLOS; MIM 270400), Cohen syndrome (CS; MIM 216550), Cornelia de Lange 
syndrome (CDLS; MIM122470), Prader–Willi Syndrome (PWS; MIM 176270) and untreated phenylketonuria see Figure 1. (1, 3, 
8-12). These syndromes share overlapping clinical features with autism including developmental delay, language impairment, 
seizures and stereotypic behaviors. The root cause of all ASD phenotypes they do not arise from the same origin (mutation). The 
3 
 
 
cause(s) when determined requires personalized treatments, the development of early detection diagnostics, and the establishment of 
preventive measures.  
 
In a vast majority of cases, the cause of ASD is idiopathic, and researchers are examining comorbidities, neural pathways, 
environmental and genetic factors. The most prevalent comorbidity, at roughly 50%, is intellectual disability (3). It has also been 
proposed that in some individuals’ neural damage associated with seizures leads to deficits associated with ASD. An estimated 20% 
of individuals diagnosed with ASD also have epilepsy (1). A full list of common and rare comorbidities is shown in Table 2.  
  
The etiology of ASD is commonly described as a genetic predisposition combined with an environmental impact these 
factors are delineated below.  
 
 
 
4.2. Genetic risk factors 
The genetic contribution to ASD has been known since the 1970s, after two identical twins were found to have the same 
condition (13). It has since been determined that the heritable rate is around 80% in identical twins and the conforming rate for 
sibling twins is around 40%.  
 
Some autistic characteristics can be observed to be part of several well-known syndromes as discussed in comorbidities 
section. Around 10% of all ASDs are classically associated with dysmorphic features and/or deformities and named Syndromic 
autism (14-16). The overall incidence of ASD in the syndrome was documented to be significantly higher than incidence of 
syndrome in the ASD cases. For instance, the highest was observed in ADSLD (80-100%) and the lowest was in Neurofibromatosis 
type 1 (17). On the other hand, incidence of the syndrome in ASD was found to be less frequent and not exceeding 5% (17). 
Remarkably the clinical presentations of the syndromic autism are extremely heterogeneous that could be attributed to differences in 
genetic background and epigenetic influences.  
 
In addition, searches into the genetics of ASD have accelerated in recent years due to the rapid advancement of DNA-
decoding technologies (18). With the identification of genetic variants related to ASD, testing at birth or in vitro may become a risk 
factor identification tool that leads to early intervention. A gender gap also emerges when deciphering etiology of ASD. There is 
recent support for a ‘female protective effect’ as an explanation for males being four to five times more likely to have the disorder 
(4, 7, 19). 
 
As technology advances, the list of genes linked to autism is growing. Many of these genes are vital for communication 
between neurons or they control the expression of other genes. Although over 400 genes have been strongly linked and 200 weakly 
linked, the contribution of each particular gene within the ASD population is very minor, with none found in more than 2% of 
patients. It is clear that genetic architecture of ASD is extremely diverse, with contributions from alleles (variant regions within a 
gene that an individual has two copies of, one being inherited from each parent) of varying frequencies. The most common 
inheritance patterns of alleles associated with ASD are a dominant variant type, while recessive inheritance patterns are rare, and X-
linked or de novo inheritance patterns are very rare. The variant types may include large chromosomal rearrangements, copy 
number variants (CNV), small insertions/deletions (indels), and single-nucleotide variants (SNVs) (20, 21). Although abundant 
variants have been associated with ASD, it is difficult to relate them with disease mechanisms. 
 
The largest class of genetic risk for ASD accounts for around 50% of the total, and is estimated to derive from common 
variants of an additive effect; almost all of which have yet to be identified (22). A further 5–10% of genetic risk is estimated from 
rare inherited and de novo variants, leaving 40% of the genetic risk, currently, undetermined. Forthcoming whole-genome 
sequencing (WGS) of complex families will extensively expand our knowledge. 
 
Using a classified approach to analyze autism-related mutations from two large whole-exome sequencing studies, it has 
been found that while those mutations did not duplicate at the single-nucleotide level, some do at the gene and pathway levels. 
These modifications combine to affect pathways involved in synaptic function, morphology, and plasticity. The results suggest that 
isolated rare mutation events are connected and recurrent at higher (gene and pathway) levels. So far, approximately 400–1000 
ASD risk genes have been identified and found to be involved in pathways that include synaptic formation, transcriptional 
regulation, and chromatin remodeling (18, 23, 24). Three explanations have been proposed for increasing replication at the gene and 
pathway levels: a smaller background space (small sample sizes), high local mutation rates, or true and recurrent disease 
mechanisms. Based on these findings, it was postulated that a gene-plus-pathway dual-hit model could describe autism genetic 
associations. This model depends on the effect of the disrupted genes and whether that effect also influences related pathways (25).  
 
Most interestingly, probands (the affected individual) did not simply harbor more variants overall, but more gene-
disrupting ones and ones that affected selected pathways. Notably, probands are 55% more likely to have gene-disrupting, and 11% 
more likely to have missense mutations, than their siblings. These variants have a tendency to repeatedly affect a number of 
signaling pathways. While at the gene level, 92 genes mapped to these pathways, at the variant level, there were 43 likely gene 
disrupting, and 75 missense mutations.  
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These pathways included the, Wnt signaling, GABAergic signaling, synaptic pathways such as neuroligin 3 (NLGN3), 
NLGN4X, neurexin 1 (NRXN1), and SH3, and multiple ankyrin repeat domains 3 (SHANK3) and glutamatergic synapse pathways, 
among others. In particular, it was noted that the canonical branch of the Wnt signaling pathway and the whole of the GABAergic 
signaling pathway are involved. It was also noted that the pathways implicated are consistent yet are separated into two modules. 
One module, through its inclusion of Wnt signaling, cell adhesion, junction, and cytoskeletal-associated pathways, highlights the 
role of synapse morphology in autism. Meanwhile, the other module underscores the role of synapse function with its inclusion of 
glutamatergic synapse, GABAergic synapse, and related processes. This suggests that the synaptic transmission and function and 
neuronal wiring and morphology have key roles in ASD. Evidence indicates that many of the genes that are mutated in ASD are 
crucial components of the activity-dependent signaling networks that regulate synapse development and plasticity. Dysregulation of 
activity-dependent signaling pathways in neurons may therefore, have a key role in the etiology of autism spectrum disorders (26) . 
 
Synaptic genes such as neuroligin 3 (NLGN3), NLGN4X, neurexin 1 (NRXN1), and SH3, and multiple ankyrin repeat 
domains 3 (SHANK3) have been involved in ASD. For instance, Neurexins act mainly at the presynaptic terminal in neurons and 
play essential roles in neurotransmission and differentiation of synapses. Some of these roles need the formation of trans-synaptic 
complexes with postsynaptic proteins such as neuroligins, LRRTM proteins or cerebellin and scaffolding proteins SHANK2 and 
SHANK3. 
 
Rare mutations and CNVs in the neurexin genes have been connected to ASD and psychiatric disorders, indicating that 
impairments of synaptic function sustained by neurexins and their binding partners possibly related to the pathomechanism of the 
ASD (27, 28). 
 
Some view autism to be a synaptic disorder. Some uncommon mutations may cause autism by interrupting some synaptic 
pathways, such as those involved with cell-cell interaction. Gene substitute studies show that autism is due to changes in activity of 
synapses and also on activity-dependent modifications. Chromosomal abnormalities and epigenetic changes deserve to be discussed 
and referenced. 
 
In addition, evidence shows that many of the genes that are mutated in ASD are vital components of the activity-
dependent signaling networks that regulate synapse development and plasticity. Dysregulation of activity-dependent signaling 
pathways in neurons may therefore, have a key role in the etiology of ASD (26).  
 
Several studies showed that impairment of neural connectivity is the most common theory for the pathogenesis of ASDs. 
For instance, irregular number of neurons as well as abnormal brain and head growth, possibly due to impaired pruning 
mechanisms, have been documented in ASDs patients (29, 30). Courchesne et al reported that 67% more neurons in the PFC of 
children with ASDs compared to controls. A subsequent study by Courchesne et al. also found that excess neurons in the PFC, that 
are eliminated via apoptosis during the prenatal and perinatal periods in just a few months in healthy controls, take years to be 
eliminated in patients with ASD, thus indicating a relationship between an increase in neurons and ASD pathology. 
 
Another region that is affected by irregular neural connectivity and important in ASD pathology is the amygdala. Children 
with ASDs have an 11% increase in the numbers of amygdalar neurons compared to controls. However, by adulthood, neurons in 
the amygdala decrease by 17% in patients with ASDs, while in controls, there is an increase by 11% (31). Abnormal populations of 
amygdalar neurons, similar to PFC, indicate dysfunctional apoptotic function (32). Clinical studies also revealed significant 
reduction of neurons in the fusiformgyrus, striatum, and cerebellum of ASD patients (33, 34). While the nature of this relationship 
is not confirmed, there is growing evidence that proteins and pathways regulating apoptosis are dysfunctional in ASDs (35). As 
these pathways are explored further, candidates for genetic manipulation arise that may provide answers about the role of apoptotic 
dysregulation in ASDs. 
 
Thus, ASD is not solely a multi-genetic, but also a multi-pathway disease, and it is eventually a synapse disease. The 
affected pathways could be a collection of genetic risk factors for autism. 
 
A de novo mutation is one that is not inherited from either parent, these types of spontaneous mutations are estimated to 
be the underlying genetic cause in between 15% and 25% of cases of ASD (36). They exhibit vast heterogeneity in size – some are 
small enough to affect a single gene or large enough to encompass many genes and clinical presentations; patients with multiple de 
novo CNVs usually have more severe phenotypes (37-44). All of these studies found that de novo SNVs have a predominantly 
paternal origin and the rate of de novo mutation frequency increases with paternal age, concordant with other studies on de novo 
mutation frequencies (45, 46). 
 
In sum, as research progresses it has become clear that autism is a multifactorial genetic disease that does not follow 
classical Mendelian inheritance (Table 3). 
 
4.3. Environmental risk factors 
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During the first eight weeks from conception some teratogens or exposure to polluted air like fine/ultrafine particulate 
matter (PM2.5), dangerous plastic items, hazardous type solvents, metals, and chemicals (e.g., PCBs, Phthalates, Phenols, fire-
resistant brominated material, etc.), or detrimental behavior such as alcohol consumption, smoking, and use of illicit medicines, 
or adverse reaction to some vaccines as well as prenatal stress/tension increase the risk of autism. In animal studies, prenatal 
exposure to viruses like rubella or cytomegalovirus activates the mother's immune response and may greatly increase the 
incidence of autism in mice. It seems that congenital rubella syndrome is the most convincing environmental cause of autism. 
However, not all of these risk factors are evidence-based or have been substantiated to be involved.  
 
In addition to the social, behavioral and communicative deficits, a requirement for an ASD diagnosis is the presence of 
these phenotypes in early childhood. This time period, from gestation through the first three years, corresponds with significant 
neurodevelopment. Through ongoing work in defining typical trajectories for maturation of neural circuits utilizing neural 
imaging, researchers have created a backdrop against which genetic alterations and the effects of adverse experience on brain 
maturation can be compared. Researchers continue to investigate periods of critical vulnerability during the development of 
neural circuits and their sensitivity to experiences and environmental exposures (9).  
 
Investigation into consequences of exposure to specific environmental factors at critical moments in time, is now a major 
field in ASD research. Examples of environmental risk factors include how low levels of folic acid may be linked to ASD in early 
but not late pregnancy, or that exposure to harmful chemicals and infections have greatest impact during the second and third 
trimester when brain growth and synapse formation is largest (9). A comprehensive list of environmental risk factors including 
prenatal, natal, and postnatal can be found in Table 2. 
 
Recent reviews point to an important role for metal neurotoxins in ASD (47, 48) and neurotoxic chemicals interaction 
with neurotransmitters (49). Both Aluminum (Al) and Mercury (Hg) emerge as the predominant neurotoxic elements. Experimental 
results indicate that the chemical form can penetrate the blood/brain barrier. Ingestion of these neurotoxic compounds by women of 
child-bearing years increases ASD risk. Exposure to neurotoxic chemicals have been shown to lead to alterations in neuro-receptor 
systems related to ASD. Intriguingly, an association was found between air pollution and ASD (50, 51). The research group found 
that high maternal exposure to particulate matter during pregnancy, especially during the third trimester, was associated with greater 
odds of a child having ASD. In a separate study, postnatal exposure to nitrogen dioxide (a traffic related air pollutant), was 
associated with increased odds of ASD. 
 
The exposure itself does not directly cause ASD, but when compounded with other risk factors may trigger changes, 
which affect neural development, and result in ASD phenotypes. It is the toxic load of chemicals, infectious, psychological, 
nutritional, and other stressors that can erode an individual’s resilience through effects on the epigenome, endocrine homeostasis, 
cell signaling, etc. ultimately overwhelming adaptive capacity (9). In searching for environmental factors, the focus is on finding 
those most prevalent, so that by reducing exposure, the greatest positive impact can occur. Thus, numerous other factor including 
environmental factors are considered to be responsible for susceptibility to autism through interaction of susceptible genes (Table 
2).  
 
4.3.1. Prenatal risk factors 
Physical, mental, and psychological well-being and the family financial situation throughout the pregnancy are important 
influencers affecting fetal development and health. An unhealthy mother who is not mentally and/or physically healthy and 
undernourished is implausible to have a healthy neonate. A set of prenatal risk factors which increase a child's susceptibility to 
autism is discussed below. 
 
4.3.1.1. Parental age 
Advanced parental age (particularly paternal age) has been identified as one of the most significant risk factors of autism 
(52-56). Several studies have showed that maternal and paternal age older than or equal to 34 years their offspring has greater risk 
of autism; however, in other studies, the relationship between child autism and the age of both parents (57) or even the age of one 
parent is ambiguous and unclear (58-62). Intriguingly, the relationship between increased risk of autism and elevated paternal age 
has been shown in few studies (55, 63-69). Particularly, a study that was conducted amongst the Iranian people in 2010 explored the 
relationship between parental age and autism risk had affirmed such association (68). Based on this study, autism risk increases by 
29% for every 10-years elevation in the fathers’ age. In other words, fathers’ aged between 34 and 39 had nearly a two-fold greater 
risk, and those who are older than 40 have more than two-fold (2.58) greater risk to have an affected child in comparison to those 
ones who are aged 25-29 years old (68). In other studies in Japan (62) and China (67), similar relationships were explored between 
paternal age and increased risk of autism. The lack of any correlation between maternal age and susceptibility to autism in these two 
mentioned studies has critical importance. The probable explanation for this phenomenon is the formation of de novo mutations in 
germline cells and modifications in DNA methylation, which can result in general epigenetic alterations in the expression of neural 
developmental genes and, finally, disorders in sperm genomic imprinting. As a result, the probability of neural impairments, such as 
autism, would be increased (46, 55, 64). Advanced paternal age also affects immune system functions, consequently, the 
development of the nervous system (63). 
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In autism studies investigating increase in maternal age, they revealed a correlation between autism chromosomal 
abnormalities and trinucleotide repeat expansion in the ovule (57-59, 70-72); and a connection between autism and the increased 
obstetric intervention at advanced maternal age (71). On the other hand, being young at gestational age potentially increases the risk 
of autism due to the lack of physical maturity, and the inability or poor maternal care. Mothers who are younger than 20 may be 
exposed to intrauterine growth retardation of fetus and preterm birth, which both are compelling factors associated with increased 
risk of autism (57, 59, 73). 
 
4.3.1.2. Maternal physical health 
Infection, a metabolic syndrome or bleeding during pregnancy are among the conditions tied to autism. Maternal bleeding 
during pregnancy is significantly associated with an elevated risk of autism, nearly 81% (53). Metabolic syndromes, including 
diabetes (53, 74) hypertension (59, 75) and obesity (75, 76) pave the way for hypoxia (oxygen deficiency) in utero (74) leading to 
retarded brain development, induction of myelination changes, alteration in membrane adhesion, and deficiency in hippocampal 
neurons (a brain area which is highly involved in autism) (77, 78). Maternal viral infections including rubella (79-81), measles, 
mumps, chicken pox (79, 82), influenza (79, 82, 83), herpes (79, 84), varicella zoster (84) and cytomegalovirus (82, 85), and 
bacterial infections such as pneumonia and syphilis in the first trimester or in the second trimester if they require hospitalization, 
distress the embryo and increase the risk of autism (79, 86). Such outcome is due to abnormal maternal immune activation and, 
consequently, elevated levels of inflammatory cytokines which affect the embryonic brain development and alter 
neuropathophysiological status ergo increasing the risk of autism (86, 87). 
 
4.3.1.3. Maternal mental health 
The family unit well-being, parental behavior, and communication patterns affect the formation of personality and 
emotions. There is an association between parental psychiatric history and the threat of developing a child with mental disorders, 
especially autism. For example, the association of parental psychiatric history such as schizophrenia causes the odd of autism to 
nearly three-fold (57, 88-91). Moreover, the relationship between the  anxiety (67, 90, 92-97), depression (88-91, 98) and 
personality disorders (88) of the mother, and the susceptibility to autism has been demonstrated in many studies. 
 
Besides mothers that are recognized as mentally ill, those who undergo considerable stress during the 21–32 weeks of 
gestation, a period of heightened plasticity for fetal formation and development (71, 99), may have irreversible effects through 
epigenetic mechanisms, expression of fetus stress response genes, and genes involved in neurodevelopment, metabolism, and 
physiology persisting across lifespan. The psychological state of the mother, especially periods of great and long-lasting stresses 
result in personality disorders such as aggression (100) causing changes in cortisol levels thus disrupting the HPA axis in the 
mother, therefore, amplifying adrenal steroids and increasing placental permeability to hormones further impacting the fetus. 
Consequently, fetal developmental epigenetic programming would be highly affected because of interrupting the fetal stress 
response system, paving the way for different physical and mental impairments including autism (98). 
 
4.3.1.4. Maternal prenatal medication use 
Use of maternal prenatal medication was suggested to increase the risk of autism. Use of prenatal psychiatric medication 
cause 68% increase in the risk of autism,  likely due to the fact that such drugs pass the placenta and disrupt the fetal development 
(53). For example, the use of antiepileptic drugs such as  valproic acid leads to fetal valproate syndrome due to increased oxidative 
stress and altered gene expression patterns, subsequently resulting in developmental delays, deficient motor activities and postnatal 
growth aberrations (82, 101-102). Moreover, it is documented that paracetamol (acetaminophen), which is widely used as an 
analgesic/antipyretic drug, induces apoptosis and necrosis similar to the legions observed in autistic brains. Additionally, 
paracetamol (acetaminophen) induces oxidative stress and immune dysregulation in humans (103). Furthermore, positive 
correlation between antidepressant medications and autism has been demonstrated in many studies (104-106). Other medications 
display increased susceptibility to autism such as thalidomide, a painkiller, (107), misoprostol, a prostaglandin analog drug for the 
prevention and treatment of gastric ulcers (108) in the first trimester, and β2-adrenergic agonists like terbutaline to treat asthma 
(109, 110). 
 
4.3.2. Familial socioeconomic status 
Considering economic, social, educational, and psychological aspects of a family's life, autistic children and their families 
are mainly of poor socioeconomic status (111). Basically, these families inevitably experience unhealthy, inappropriate sociality 
and unrehabilitated life conditions because of their financial problems, and occupational and psychological stresses (112-114). The 
inaccessibility to health care and recreational facilities compound issues and impair physical health (115). Furthermore, exposure to 
stress and anxiety (such as shared living quarters with other couples or families) imposes continued psychological tension for the 
parents, especially pregnant mother, thus increasing susceptibility to child autism during pregnancy (67, 93, 94). 
 
Isolation of a mother and breakdown in communications and social interactions negatively affect both the mother and the 
fetus (116). There are also reportd of existence of a relationship between the parental education and the risk of autism (111, 117-
119). 
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4.3.3. Other prenatal risk factors  
Results in Table 2 suggests prenatal risk factors that may increase the fetal risk of autism. Abnormal gestational age, pre-
term (<35 weeks) and post-term pregnancy (>42 weeks), are associated with a significantly increased risk of autism (53, 57, 67, 
118, 120, 121). Prenatal risk factors such as bleeding during pregnancy and natal risk factors such as fetal complications including 
fetal distress, umbilical-cord complications such as fetal nuchal cord and cesarean delivery (26% increased risk of autism) (53) are 
all involved in hypoxia (lack of oxygen), consequently increasing the susceptibility to autism (53, 59, 70, 121). Fetal nuchal cord 
occurrence was significantly more frequent among children with autism (23.2%) when compared to controls (6.3%). This 
complication causes fetal blood deficiency, oxygen, and nutrition. If the inadequate blood flow is severe or long-lasting it would 
affect fetal brain development and damage the newborn central nervous system (110). Three brain regions, including basal ganglia, 
hippocampus, and lateral ventricles, are highly known to be highly vulnerable to hypoxia (70). Autistic children's brain exhibit 
larger lateral ventricles, morphological hippocampal abnormalities, and increased dopaminergic activity, which are all inducible by 
hypoxia (122). 
 
4.3.4. Postnatal risk factors  
Postnatal risk factors play a crucial role in susceptibility to autism. A set of such risk factors is included in Table 2. Low 
birth weight, jaundice, and postnatal infections are some of the most significant risk factors. A neonate with a birth weight, which is 
determined based on three potential factors (genetic growth potential, duration of pregnancy and rate of fetal growth), less than 
2500 g is considered a low birth weight and has a two-fold increased odds ratio of autism (53, 57, 59, 119, 123). 
 
Postnatal jaundice is the result of high bilirubin production caused by increased breakdown of fetal erythrocytes and a low 
hepatic excretory capacity resulting from general immaturity of the liver. Postnatal jaundice can be associated with death during a 
sensitive period (around the 40 weeks of pregnancy) or susceptibility to mental disorders, especially a four-fold increase in autism is 
noted if it survives (53, 57, 67, 124, 125). In addition to prenatal maternal infection during pregnancy, postnatal infections such as 
meningitis, mumps, varicella, fever of unknown origin, and ear infections (126) during the first 30 days of life are correlated with a 
high risk of autism (127, 128). 
 
5. DIAGNOSIS AND MANAGEMENT 
 
5.1. Criteria for clinical diagnosis 
In 1943, the psychiatrist Leo Kanner published a paper describing “children whose condition differed so markedly and 
uniquely from anything reported so far” (4, p. 217). The author believed that the children suffer from a yet unnamed disorder. The 
severity varied amongst the cases, but from birth all displayed an “extreme autistic aloneness” (4, p. 242), a powerful desire for 
sameness, and the ability to interact intelligently with objects, but not with people (129). It is from Kanner and, later psychiatrist, 
Hans Asperger’s observations that the current classification of ASD arose. 
 
Today, the paths to an ASD diagnosis vary by country, practitioner training, as well as the age of the patient. Children 
around the world are routinely screened during wellness visits, or in school settings. A list of popular global screening tools is 
provided in Table 4. A positive diagnosis via screening tool is sufficient in many countries to access treatment services. In the 
United Kingdom and the United States, diagnosis is made by a developmental pediatrician, psychologist, or psychiatrist using 
either the International Classification of Diseases Version 10 (ICD-10) (130), or the Diagnostic and Statistical Manual of Mental 
Disorders, 5th Edition (DSM-5) (131). In the Arab world, the use of ADI-R or ADOS as diagnostic tools, with clinical 
observations based on DSM-4 and DSM-5 criteria is typical. Amongst the Gulf States, Qatar uses ADOS as the primary 
diagnostic tool. 
 
The DSM-5 is considered to be the gold standard in ASD diagnosis and the ICD closely mirrors it. Similar to the children 
Kanner first described, the DSM-5 classifies autism spectrum disorder based on deficits in social communication, and the presence 
of restricted, repetitive behaviors, giving each of these two categories a rating between 1-3 based on severity. A rating of 1 is the 
lowest and indicates that the child has milder symptoms and ‘requires support’ and a rating of 3 indicates that the child’s symptoms 
are severe and ‘requires very substantial support’. A diagnosis also includes clinical notes and specifies any accompanying 
intellectual impairments, language impairments, medical or genetic conditions, or environmental factors. The DSM and the ICD, 
have expanded criteria of diagnosis in subsequent editions; notably, the DSM-5’s reclassification of Asperger’s and pervasive 
developmental disorder not otherwise specified (PDD-NOS) now falls under a single diagnosis of ASD (131). 
 
While developmental concerns are noted in approximately 85% of children before the age of three, the average age for 
diagnosis is four (3). Concerns may include lack of eye contact, not meeting developmental milestones, lack of affection and 
reciprocal social interaction, as well as poor language development. Popular screening tools such as the Modified Checklist for 
Autism in Toddlers (M-CHAT) (132) are available online for free, and provide an early resource to caregivers when initially 
noticing concerning behavior, before seeking professional help. A growing awareness of autism has led many adults, who were not 
diagnosed as children, to seek treatment. In adults, the diagnosis generally relies on self-report or informant questionnaires, 
observation guides, and clinical interviews (9, 133). Although, early diagnosis remains a challenge. Nevertheless, a team of 
investigators from the Cleveland Clinic Children’s Center for Autism has developed what may become ASD’s first objective 
diagnostic aid: an autism risk index based on remote eye-gaze tracking, which is proving to be remarkably accurate (134) (Table 4). 
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As of 2010, there were an estimated 52 million cases of ASD worldwide. Given the current prevalence estimates of ASD 
when comorbidities such as learning disabilities (dyslexia), epilepsy and intellectual disability are factored in, the diagnosis rate 
jumps. The causes of ASD are not clear-cut, nonetheless evidence suggests that a number of environmental and genetic factors are 
at play (7, 19).  
 
5.2. Behavioral and psychological management and prognosis  
Once a diagnosis of ASD has been established, deficits are treated with a multifaceted team approach. (4)Treatments 
regularly include occupational, behavioral, speech, and play therapies. There are no pharmacological treatments for ASD, though 
many individuals receive medications to address comorbidities, such as seizures, and attention deficit hyperactivity disorder 
(ADHD). In some areas, children may receive support services in schools, including special education programs that target common 
comorbidities (discussed below) including learning disorders, and intellectual disabilities (4). 
 
The prognosis for an individual with ASD is as heterogeneous as the diagnosis. Those on the mild end of the spectrum, 
commonly referred to as Aspergers, with average to high IQ are often able to enter mainstream education, progressing into the 
workplace and through therapeutic support improving skills in social communication. It is not uncommon for individuals at the 
highest end, many of whom would have previously received a diagnosis of Aspergers, to embrace and capitalize on their atypical 
neurodevelopment. For example, while an interest in objects, rigid desire for sameness, routine, and detail can hinder social 
interaction, creativity and flexibility, those same qualities may be very useful in a field that requires a restricted focus on objects, 
precision, and strict adherence to routine.  
 
For those individuals with a severe diagnosis, prognosis is far less positive. Severe cases may never learn to 
communicate, and they remain in a world that is withdrawn from peers and family. The focus of treatment for ASD is personalized 
to the needs of the individual, with a goal to improve quality life of the patient and those around them. Family and caregivers often 
struggle to relate due to barriers in communicating with those suffering with ASD, and are encouraged frequently as part of therapy 
to find shared enjoyment in activities that promote bonding.  
 
In addition to traditional therapies, families and the individuals with ASD may seek out support from the community. This 
can include support through online groups or websites. Autism Speaks (135) is one such popular website, allowing people to 
connect, access the latest research, and receive moral support. Community and business support for those on the spectrum is 
becoming more widely available, whether in the form of activities such as playgroups, gymnastics or music classes, that specifically 
target young ASD individuals, or job programs such as ‘The Microsoft Autism Hiring Program’ (136), which helps qualified ASD 
adults integrate in the workplace. 
 
6. THE ROLE OF DIAGNOSIS IN RESEARCH 
 
6.1. Heterogeneity of research participants 
The broad criteria for ASD diagnosis leads to a heterogeneous pool of research participants. Lynn Waterhouse in her 
book, Rethinking Autism (137) proposes the abandonment of the DSM-5 diagnosis of ASD for research. Other researchers 
recommend a change to the DSM-5 to include more subtypes of ASD (138). Even without a reclassification, one of the largest 
ASD research projects to date, SPARK by the Simons Foundation (139), narrows the pool of participants through a series of 
questionnaires, removing those who have known genetic conditions, or epilepsy.  
 
6.2. Benefits of single disorder classification 
It would seem that abandoning the umbrella classification of ASD would assist research, but the abandonment also 
creates few obstacles. Due to the prevalence of the current ASD diagnosis, it has become a priority health initiative in many 
countries. One such country is Qatar where a national plan was launched in April 2017 (19). Widespread public and financial 
support may not be as readily available if diagnostic criteria changes and the prevalence rates drop. The current umbrella 
classification of ASD also allows individuals in need to easily qualify for support services, and finally it brings together 
caregivers and individuals who are dealing with similar phenotypic behaviors and gives them support, regardless of cause (4, 7). 
National plans put an issue on the policy agenda. In moving forward, the priority is then given to ensure that autistic people, their 
families and caregivers have access to effective support through the diagnostic process and post-diagnosis, and that requisite 
educational support is available, as in Qatar’s case (4). 
 
6.3. Future of diagnostics: clinical genetic testing 
The standard of practice for diagnosis of ASD is first by microarray for detection of large and submicroscopic CNV, 
followed by WES or WGS. Other genomic techniques such as transcriptomics and epigenomics could also be employed to lead to 
an enhanced understanding of the molecular mechanisms involved in ASD, and ultimately inform clinical care. Cell-free DNA 
(cf DNA) testing is becoming an indispensable diagnostic tool. This type of testing or screening is often called noninvasive 
prenatal testing (NIPT). With next-generation sequencing techniques or single nucleotide polymorphism-based approaches, fetal 
cf DNA in maternal plasma can be analyzed to screen for testing genetic disorders or related conditions. As stated previously, the 
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use of genetic testing or clinical genomics as an in vitro screen tool, may be a promising way to identify individuals at risk for 
autism.  
 
Progress in clinical care for ASD will continue to be contingent on multidisciplinary, collaborative research efforts. 
Efforts are currently underway to identify functional, genetic-ontological subtypes that may provide additional utility with regard 
to clinical intervention. This includes investigation of broader phenotypes associated with gene disruptions that share molecular 
properties, for example, genes regulated by the CHD8 protein (140, 141). Identification of measurable neurological effects of 
gene disruptions, such as an electrophysiological (EEG) signature, could translate to meaningful ASD biomarkers that are 
essential for clinical treatment trials (142). Meanwhile, development of pharmacotherapies for genetic subtypes, such as SCN2A, 
will require increased knowledge about the timing of genetic expression and reversibility of neurodevelopmental impairment. 
Thus, continued comprehensive phenotyping will be essential to the success of clinical trials for genetic subtypes of ASD (140). 
 
 
 
7. POTENTIAL FUTURE GENOMIC TREATMENTS  
 
Gene therapy seems to hold promise as potential treatment for ASD. Recently, the first preclinical studies in monogenic 
ASD, involving both gene replacement and silencing have been reported. With increased understanding of ASD etiology, this 
work can be extended to polygenic ASD (143). 
 
Another possible futuristic treatment is the use of genome editing. We believe the CRISPR-gene editing strategies will 
soon be increasingly utilized in ASD models to both recapitulate pathophysiology and alleviate neurodevelopmental conditions. 
For example, a recent study utilized CRISPR-Gold, a novel nanoparticle delivery method, to target striatal mGluR5 levels in FXS 
mice. In addition to a successful reduction in mGluR5 levels, the study revealed subsequent rescue of repetitive behaviors in FXS 
mice (144). 
 
8. CONCLUSION 
 
The economic impact associated with ASD is substantial, and includes direct medical and non-medical, and indirect 
productivity costs. Studies estimate the lifetime cost of caring for an individual with ASD to be $2.2 million in the US, and £1.5 
million in the UK; though the cost drops to $1.4 million in the US and £0.92 million in the UK for ASD without comorbid 
conditions. In addition, if unrecognized or untreated, ASD can contribute to poor educational attainment and difficulty with 
employment, leading to negative economic implications. Recent estimates of the total economic impact of ASD in the US in 2015, 
based on direct medical, non-medical and productivity costs combined, totaled $268 billion – ranging from 0.9 to 2% of gross 
domestic product (GDP). This amount is expected to rise to $461 billion (ranging from 0.99 to 3.6% of GDP) by 2025. These costs 
are on par with recent estimates for ‘silent epidemics’ such as diabetes. Indeed, the burden of ASD appears to exceed the cost of the 
traditional enemies of health. However, what sets ASD apart from other non-communicable diseases – such as heart disease, cancer, 
stroke and hypertension – are the significantly higher non-medical costs when compared to direct medical costs. There is also 
suggestion that comorbidities of ASD tend to amplify burden to the society and afflicted individuals alike (7, 19). 
 
In this review, we offered a summary of ASD clinical diagnostic criteria and provided an insight into ongoing research 
toward environmental factors, genetic mutations, and neural pathways. We also explained trends in clinical genetic testing. The 
future for individuals suffering from less severe forms of ASD is positive. It is hoped that through early behavioral screenings, 
genetic testing, identification of environmental risk factors as well as a better understanding of neural development, the number 
of individuals suffering from autistic phenotypes may be greatly reduced. While there is much work still to be done in 
understanding and treating ASD, there are important steps that can be taken now. First, continued awareness programs so that 
children are identified and treated as early as possible. Second, pre-natal and pre-pregnancy awareness of environmental factors, 
including recommendations against consanguineous marriages, information regarding optimal maternal nutrition and the 
importance of limiting exposure to toxins and pollutants. Finally, the expansion of genetic screening, and early post-natal 
monitoring of infant feeding, nutrition, eye contact, will help to provide the earliest treatment possible.  
  
9. ACKNOWLEDGEMENTS 
 
The authors want to thank their respective institutions for their continued support. The authors declare no conflict of 
interest.  
 
10 
 
 
10. REFERENCES 
 
1. F. Doshi-Velez, Y. Ge and I. Kohane: Comorbidity clusters in autism spectrum disorders: an electronic health record time-
series analysis. Pediatrics, 133(1), e54-63 (2014)  
  
2. S. Nardone and E. Elliott: The Interaction between the Immune System and Epigenetics in the Etiology of Autism Spectrum 
Disorders. Front Neurosci, 10, 329 (2016)  
  
3. J. Baio, L. Wiggins, D. L. Christensen, M. J. Maenner, J. Daniels, Z. Warren, M. Kurzius-Spencer, W. Zahorodny, C. 
Robinson Rosenberg, T. White, M. S. Durkin, P. Imm, L. Nikolaou, M. Yeargin-Allsopp, L. C. Lee, R. Harrington, M. Lopez, R. 
T. Fitzgerald, A. Hewitt, S. Pettygrove, J. N. Constantino, A. Vehorn, J. Shenouda, J. Hall-Lande, K. Van Naarden Braun and N. 
F. Dowling: Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities 
Monitoring Network, 11 Sites, United States, 2014. MMWR Surveill Summ, 67(6), 1-23 (2018) 
  
4. Karen Guldberg, Elaine Ashbee, Lila Kossyvaki, Ryan Bradley and A. Basulayyim: Meeting the Needs of Pupils with Autism 
in Qatar: Moving forward. In, Report of WISE 2017 Summit (2017)  
  
5. M. Elsabbagh, G. Divan, Y. J. Koh, Y. S. Kim, S. Kauchali, C. Marcin, C. Montiel-Nava, V. Patel, C. S. Paula, C. Wang, M. 
T. Yasamy and E. Fombonne: Global prevalence of autism and other pervasive developmental disorders. Autism Res, 5(3), 160-
79 (2012)  
  
6. K. Hoffman, M. G. Weisskopf, A. L. Roberts, R. Raz, J. E. Hart, K. Lyall, E. M. Hoffman, F. Laden and V. M. Vieira: 
Geographic Patterns of Autism Spectrum Disorder Among Children of Participants in Nurses’ Health Study II. Am J Epidemiol, 
186(7), 834-842 (2017) 
  
7. Kerim M Munir, Tara A Lavelle, David T Helm, Didi Thompson, Jessica Prestt and Muhammad W Azeem: AUTISM A 
GLOBAL FRAMEWORK FOR ACTION. In, Report of the WISH Autism Forum 2016 (2016)  
  
8. X. L. Yang, S. Liang, M. Y. Zou, C. H. Sun, P. P. Han, X. T. Jiang, W. Xia and L. J. Wu: Are gastrointestinal and sleep 
problems associated with behavioral symptoms of autism spectrum disorder? Psychiatry Res, 259, 229-235 (2018) 
  
9. I. Hertz-Picciotto, R. J. Schmidt and P. Krakowiak: Understanding environmental contributions to autism: Causal concepts and 
the state of science. Autism Res, 11(4), 554-586 (2018) 
  
10. A. Mannion and G. Leader: Comorbidity in autism spectrum disorder: A literature review. Research in Autism Spectrum 
Disorders, 7(12), 1595-1616 (2013)  
  
11. A. Nahar, H. Thippeswamy, M. S. Shanker Reddy, M. T. Kishore and S. K. Chaturvedi: Psychiatric comorbidity in persons 
with high-functioning autism spectrum disorders: Findings from a tertiary care neuropsychiatric hospital. Asian J Psychiatr, 
(2018)  
  
12. J. L. Matson and R. L. Goldin: Comorbidity and autism: Trends, topics and future directions. Research in Autism Spectrum 
Disorders, 7(10), 1228-1233 (2013)  
  
13. D. A. Treffert: Epidemiology of infantile autism. Arch Gen Psychiatry, 22(5), 431-8 (1970)  
  
14. C. Lintas and A. M. Persico: Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist. J Med Genet, 
46(1), 1-8 (2009)  
  
15. B. Devlin and S. W. Scherer: Genetic architecture in autism spectrum disorder. Curr Opin Genet Dev, 22(3), 229-37 (2012) 
  
16. H. V. Toriello: Approach to the genetic evaluation of the child with autism. Pediatr Clin North Am, 59(1), 113-28, xi (2012)  
  
17. A. M. Persico and V. Napolioni: Autism genetics. Behav Brain Res., 251, 95-112 (2013)   
  
18. D. H. Geschwind and M. W. State: Gene hunting in autism spectrum disorder: on the path to precision medicine. Lancet 
Neurol, 14(11), 1109-20 (2015) 
  
19. WISH: Autism In,  (2018)  
  
20. S. De Rubeis and J. D. Buxbaum: Genetics and genomics of autism spectrum disorder: embracing complexity. Hum Mol 
Genet, 24(R1), R24-31 (2015) 
11 
 
 
  
21. L. de la Torre-Ubieta, H. Won, J. L. Stein and D. H. Geschwind: Advancing the understanding of autism disease mechanisms 
through genetics. Nat Med, 22(4), 345-61 (2016)  
  
22. T. Gaugler, L. Klei, S. J. Sanders, C. A. Bodea, A. P. Goldberg, A. B. Lee, M. Mahajan, D. Manaa, Y. Pawitan, J. Reichert, 
S. Ripke, S. Sandin, P. Sklar, O. Svantesson, A. Reichenberg, C. M. Hultman, B. Devlin, K. Roeder and J. D. Buxbaum: Most 
genetic risk for autism resides with common variation. Nature Genetics, 46, 881 (2014) 
  
https://www.nature.com/articles/ng.3039#supplementary-information 
  
23. S. De Rubeis, X. He, A. P. Goldberg, C. S. Poultney, K. Samocha, A. E. Cicek, Y. Kou, L. Liu, M. Fromer, S. Walker, T. 
Singh, L. Klei, J. Kosmicki, F. Shih-Chen, B. Aleksic, M. Biscaldi, P. F. Bolton, J. M. Brownfeld, J. Cai, N. G. Campbell, A. 
Carracedo, M. H. Chahrour, A. G. Chiocchetti, H. Coon, E. L. Crawford, S. R. Curran, G. Dawson, E. Duketis, B. A. Fernandez, 
L. Gallagher, E. Geller, S. J. Guter, R. S. Hill, J. Ionita-Laza, P. Jimenz Gonzalez, H. Kilpinen, S. M. Klauck, A. Kolevzon, I. 
Lee, I. Lei, J. Lei, T. Lehtimaki, C. F. Lin, A. Ma'ayan, C. R. Marshall, A. L. McInnes, B. Neale, M. J. Owen, N. Ozaki, M. 
Parellada, J. R. Parr, S. Purcell, K. Puura, D. Rajagopalan, K. Rehnstrom, A. Reichenberg, A. Sabo, M. Sachse, S. J. Sanders, C. 
Schafer, M. Schulte-Ruther, D. Skuse, C. Stevens, P. Szatmari, K. Tammimies, O. Valladares, A. Voran, W. Li-San, L. A. Weiss, 
A. J. Willsey, T. W. Yu, R. K. Yuen, D. D. D. Study, A. Homozygosity Mapping Collaborative for, U. K. Consortium, E. H. 
Cook, C. M. Freitag, M. Gill, C. M. Hultman, T. Lehner, A. Palotie, G. D. Schellenberg, P. Sklar, M. W. State, J. S. Sutcliffe, C. 
A. Walsh, S. W. Scherer, M. E. Zwick, J. C. Barett, D. J. Cutler, K. Roeder, B. Devlin, M. J. Daly and J. D. Buxbaum: Synaptic, 
transcriptional and chromatin genes disrupted in autism. Nature, 515(7526), 209-15 (2014)  
  
24. M. Ronemus, I. Iossifov, D. Levy and M. Wigler: The role of de novo mutations in the genetics of autism spectrum disorders. 
Nat Rev Genet, 15(2), 133-41 (2014)  
  
25. W. Luo, C. Zhang, Y.-h. Jiang and C. R. Brouwer: Systematic reconstruction of autism biology from massive genetic 
mutation profiles. Science Advances, 4(4), e1701799 (2018)  
  
26. D. H. Ebert and M. E. Greenberg: Activity-dependent neuronal signalling and autism spectrum disorder. Nature, 493(7432), 
327 (2013) 
  
27. C. Reissner, F. Runkel and M. Missler: Neurexins. Genome Biol., 14(9), 213 (2013)  
  
28. T. Bourgeron: A synaptic trek to autism. Curr. Opin. Neurobiol., 19(2), 231--234 (2009)  
  
29. E. Courchesne, K. Pierce, C. M. Schumann, E. Redcay, J. A. Buckwalter, D. P. Kennedy and J. Morgan: Mapping early brain 
development in autism. Neuron, 56(2), 399--413 (2007)  
  
30. E. Courchesne, K. Campbell and S. Solso: Brain Growth Across the Life Span in Autism: Age-Specific Changes in 
Anatomical Pathology. Brain Res., 1380, 138 (2011)  
  
31. T. A. Avino, N. Barger, M. V. Vargas, E. L. Carlson, D. G. Amaral, M. D. Bauman and C. M. Schumann: Neuron numbers 
increase in the human amygdala from birth to adulthood, but not in autism. Proc. Natl. Acad. Sci. U.S.A., 115(14), 3710--3715 
(2018)  
  
32. J. T. Morgan, N. Barger, D. G. Amaral and C. M. Schumann: Stereological Study of Amygdala Glial Populations in 
Adolescents and Adults with Autism Spectrum Disorder. PLoS One, 9(10), e110356 (2014) 
  
33. I. A. J. van Kooten, S. J. M. C. Palmen, P. von Cappeln, H. W. M. Steinbusch, H. Korr, H. Heinsen, P. R. Hof, H. van 
Engeland and C. Schmitz: Neurons in the fusiform gyrus are fewer and smaller in autism. Brain, 131(Pt), 4 (2008)  
  
34. J. Wegiel, M. Flory, I. Kuchna, K. Nowicki, S. Y. Ma, H. Imaki, J. Wegiel, I. L. Cohen, E. London, T. Wisniewski and W. T. 
Brown: Stereological study of the neuronal number and volume of 38 brain subdivisions of subjects diagnosed with autism 
reveals significant alterations restricted to the striatum, amygdala and cerebellum. Acta Neuropathol Commun., 2 (2014) 
  
35. F. Zeidán-Chuliá, A. B. Salmina, N. A. Malinovskaya, M. Noda, A. Verkhratsky and J. C. F. Moreira: The glial perspective 
of autism spectrum disorders. Neurosci. Biobehav. Rev., 38, 160--72 (2014) 
  
36. M. Ronemus, I. Iossifov, D. Levy and M. Wigler: The role of de novo mutations in the genetics of autism spectrum disorders. 
Nat Rev Genet., 15, 133 (2014) 
  
12 
 
 
37. S. Bundey, C. Hardy, S. Vickers, M. W. Kilpatrick and J. A. Corbett: Duplication of the 15q11-13 region in a patient with 
autism, epilepsy and ataxia. Dev Med Child Neurol, 36(8), 736-42 (1994)  
  
38. S. E. Fine, A. Weissman, M. Gerdes, J. Pinto-Martin, E. H. Zackai, D. M. McDonald-McGinn and B. S. Emanuel: Autism 
spectrum disorders and symptoms in children with molecularly confirmed 22q11.2 deletion syndrome. J Autism Dev Disord, 
35(4), 461-70 (2005)  
  
39. N. S. Thomas, A. J. Sharp, C. E. Browne, D. Skuse, C. Hardie and N. R. Dennis: Xp deletions associated with autism in three 
females. Hum Genet, 104(1), 43-8 (1999)  
  
40. L. A. Weiss, Y. Shen, J. M. Korn, D. E. Arking, D. T. Miller, R. Fossdal, E. Saemundsen, H. Stefansson, M. A. Ferreira, T. 
Green, O. S. Platt, D. M. Ruderfer, C. A. Walsh, D. Altshuler, A. Chakravarti, R. E. Tanzi, K. Stefansson, S. L. Santangelo, J. F. 
Gusella, P. Sklar, B. L. Wu, M. J. Daly and C. Autism: Association between microdeletion and microduplication at 16p11.2 and 
autism. N Engl J Med, 358(7), 667-75 (2008) 
  
41. R. A. Kumar, S. KaraMohamed, J. Sudi, D. F. Conrad, C. Brune, J. A. Badner, T. C. Gilliam, N. J. Nowak, E. H. Cook, Jr., 
W. B. Dobyns and S. L. Christian: Recurrent 16p11.2 microdeletions in autism. Hum Mol Genet, 17(4), 628-38 (2008) 
  
42. S. J. Sanders, A. G. Ercan-Sencicek, V. Hus, R. Luo, M. T. Murtha, D. Moreno-De-Luca, S. H. Chu, M. P. Moreau, A. R. 
Gupta, S. A. Thomson, C. E. Mason, K. Bilguvar, P. B. Celestino-Soper, M. Choi, E. L. Crawford, L. Davis, N. R. Wright, R. M. 
Dhodapkar, M. DiCola, N. M. DiLullo, T. V. Fernandez, V. Fielding-Singh, D. O. Fishman, S. Frahm, R. Garagaloyan, G. S. 
Goh, S. Kammela, L. Klei, J. K. Lowe, S. C. Lund, A. D. McGrew, K. A. Meyer, W. J. Moffat, J. D. Murdoch, B. J. O'Roak, G. 
T. Ober, R. S. Pottenger, M. J. Raubeson, Y. Song, Q. Wang, B. L. Yaspan, T. W. Yu, I. R. Yurkiewicz, A. L. Beaudet, R. M. 
Cantor, M. Curland, D. E. Grice, M. Gunel, R. P. Lifton, S. M. Mane, D. M. Martin, C. A. Shaw, M. Sheldon, J. A. Tischfield, C. 
A. Walsh, E. M. Morrow, D. H. Ledbetter, E. Fombonne, C. Lord, C. L. Martin, A. I. Brooks, J. S. Sutcliffe, E. H. Cook, Jr., D. 
Geschwind, K. Roeder, B. Devlin and M. W. State: Multiple recurrent de novo CNVs, including duplications of the 7q11.23 
Williams syndrome region, are strongly associated with autism. Neuron, 70(5), 863-85 (2011)  
  
43. C. R. Marshall, A. Noor, J. B. Vincent, A. C. Lionel, L. Feuk, J. Skaug, M. Shago, R. Moessner, D. Pinto, Y. Ren, B. 
Thiruvahindrapduram, A. Fiebig, S. Schreiber, J. Friedman, C. E. Ketelaars, Y. J. Vos, C. Ficicioglu, S. Kirkpatrick, R. Nicolson, 
L. Sloman, A. Summers, C. A. Gibbons, A. Teebi, D. Chitayat, R. Weksberg, A. Thompson, C. Vardy, V. Crosbie, S. Luscombe, 
R. Baatjes, L. Zwaigenbaum, W. Roberts, B. Fernandez, P. Szatmari and S. W. Scherer: Structural variation of chromosomes in 
autism spectrum disorder. Am J Hum Genet, 82(2), 477-88 (2008) 
  
44. R. Anney, L. Klei, D. Pinto, R. Regan, J. Conroy, T. R. Magalhaes, C. Correia, B. S. Abrahams, N. Sykes, A. T. Pagnamenta, 
J. Almeida, E. Bacchelli, A. J. Bailey, G. Baird, A. Battaglia, T. Berney, N. Bolshakova, S. Bolte, P. F. Bolton, T. Bourgeron, S. 
Brennan, J. Brian, A. R. Carson, G. Casallo, J. Casey, S. H. Chu, L. Cochrane, C. Corsello, E. L. Crawford, A. Crossett, G. 
Dawson, M. de Jonge, R. Delorme, I. Drmic, E. Duketis, F. Duque, A. Estes, P. Farrar, B. A. Fernandez, S. E. Folstein, E. 
Fombonne, C. M. Freitag, J. Gilbert, C. Gillberg, J. T. Glessner, J. Goldberg, J. Green, S. J. Guter, H. Hakonarson, E. A. Heron, 
M. Hill, R. Holt, J. L. Howe, G. Hughes, V. Hus, R. Igliozzi, C. Kim, S. M. Klauck, A. Kolevzon, O. Korvatska, V. Kustanovich, 
C. M. Lajonchere, J. A. Lamb, M. Laskawiec, M. Leboyer, A. Le Couteur, B. L. Leventhal, A. C. Lionel, X. Q. Liu, C. Lord, L. 
Lotspeich, S. C. Lund, E. Maestrini, W. Mahoney, C. Mantoulan, C. R. Marshall, H. McConachie, C. J. McDougle, J. McGrath, 
W. M. McMahon, N. M. Melhem, A. Merikangas, O. Migita, N. J. Minshew, G. K. Mirza, J. Munson, S. F. Nelson, C. Noakes, 
A. Noor, G. Nygren, G. Oliveira, K. Papanikolaou, J. R. Parr, B. Parrini, T. Paton, A. Pickles, J. Piven, D. J. Posey, A. Poustka, 
F. Poustka, A. Prasad, J. Ragoussis, K. Renshaw, J. Rickaby, W. Roberts, K. Roeder, B. Roge, M. L. Rutter, L. J. Bierut, J. P. 
Rice, J. Salt, K. Sansom, D. Sato, R. Segurado, L. Senman, N. Shah, V. C. Sheffield, L. Soorya, I. Sousa, V. Stoppioni, C. 
Strawbridge, R. Tancredi, K. Tansey, B. Thiruvahindrapduram, A. P. Thompson, S. Thomson, A. Tryfon, J. Tsiantis, H. Van 
Engeland, J. B. Vincent, F. Volkmar, S. Wallace, K. Wang, Z. Wang, T. H. Wassink, K. Wing, K. Wittemeyer, S. Wood, B. L. 
Yaspan, D. Zurawiecki, L. Zwaigenbaum, C. Betancur, J. D. Buxbaum, R. M. Cantor, E. H. Cook, H. Coon, M. L. Cuccaro, L. 
Gallagher, D. H. Geschwind, M. Gill, J. L. Haines, J. Miller, A. P. Monaco, J. I. Nurnberger, Jr., A. D. Paterson, M. A. Pericak-
Vance, G. D. Schellenberg, S. W. Scherer, J. S. Sutcliffe, P. Szatmari, A. M. Vicente, V. J. Vieland, E. M. Wijsman, B. Devlin, 
S. Ennis and J. Hallmayer: A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet, 19(20), 4072-82 
(2010)  
  
45. J. A. Chen, O. Penagarikano, T. G. Belgard, V. Swarup and D. H. Geschwind: The emerging picture of autism spectrum 
disorder: genetics and pathology. Annu Rev Pathol, 10, 111-44 (2015)  
  
46. A. Kong, M. L. Frigge, G. Masson, S. Besenbacher, P. Sulem, G. Magnusson, S. A. Gudjonsson, A. Sigurdsson, A. 
Jonasdottir, A. Jonasdottir, W. S. Wong, G. Sigurdsson, G. B. Walters, S. Steinberg, H. Helgason, G. Thorleifsson, D. F. 
Gudbjartsson, A. Helgason, O. T. Magnusson, U. Thorsteinsdottir and K. Stefansson: Rate of de novo mutations and the 
importance of father's age to disease risk. Nature, 488(7412), 471-5 (2012)  
  
13 
 
 
47. K. Schofield: The Metal Neurotoxins: An Important Role in Current Human Neural Epidemics? Int J Environ Res Public 
Health, 14(12) (2017) 
  
48. K. Schofield: Autism, Chemicals, Probable Cause and Mitigation: A New Examination. Autism-Open Access, 6(4), 1--27 
(2016) 
  
49. I. Quaak, M. R. Brouns and M. V. de Bor: The Dynamics of Autism Spectrum Disorders: How Neurotoxic Compounds and 
Neurotransmitters Interact. Int J Environ Res Public Health, 10(8), 3384-3408 (2013)  
  
50. Raz R, Roberts AL, Lyall K, Hart JE, Just AC, Laden F and W. MG: Autism spectrum disorder and particulate matter air 
pollution before, during, and after pregnancy: a nested case–control analysis within the Nurses’ Health Study II cohort. Environ 
Health Perspect (123), 264–270 (2015)  
  
51. A. E. Kalkbrenner, G. C. Windham, C. Zheng, R. McConnell, N. L. Lee, J. J. Schauer, B. Thayer, J. Pandey and H. E. Volk: 
Air Toxics in Relation to Autism Diagnosis, Phenotype, and Severity in a U.S. Family-Based Study. Environ Health Perspect, 
126(3), 037004 (2018)  
  
52. M. S. Durkin, M. J. Maenner, C. J. Newschaffer, L.-C. Lee, C. M. Cunniff, J. L. Daniels, R. S. Kirby, L. Leavitt, L. Miller, 
W. Zahorodny and L. A. Schieve: Advanced Parental Age and the Risk of Autism Spectrum Disorder. Am J Epidemiol., 168(11), 
1268 (2008) 
  
53. H. Gardener, D. Spiegelman and S. L. Buka: Prenatal Risk Factors for Autism: A Comprehensive Meta-analysis. Br J 
Psychiatry, 195(1), 7 (2009) 
  
54. B. K. Lee and J. J. McGrath: Advancing parental age and autism: multifactorial pathways. Trends Mol. Med., 21(2), 118--125 
(2015) 
  
55. E. T. Parner, S. Baron-Cohen, M. B. Lauritsen, M. Jørgensen, L. A. Schieve, M. Yeargin-Allsopp and C. Obel: Parental Age 
and Autism Spectrum Disorders. Annals of epidemiology, 22(3), 143 (2012) 
  
56. J. F. Shelton, D. J. Tancredi and I. Hertz-Picciotto: Independent and dependent contributions of advanced maternal and 
paternal ages to autism risk. Autism Res., 3(1), 30--39 (2010) 
  
57. H. J. Larsson, W. W. Eaton, K. M. Madsen, M. Vestergaard, A. V. Olesen, E. Agerbo, D. Schendel, P. Thorsen and P. B. 
Mortensen: Risk factors for autism: perinatal factors, parental psychiatric history, and socioeconomic status. Am. J. Epidemiol., 
161(10), 916--925 (2005) 
  
58. E. J. Glasson, C. Bower, B. Petterson, N. de Klerk, G. Chaney and J. F. Hallmayer: Perinatal factors and the development of 
autism: a population study. Arch. Gen. Psychiatry, 61(6), 618--627 (2004) 
  
59. C. M. Hultman, P. Sparén and S. Cnattingius: Perinatal risk factors for infantile autism. Epidemiology, 13(4), 417--423 
(2002)  
  
60. M. B. Lauritsen, C. B. Pedersen and P. B. Mortensen: Effects of familial risk factors and place of birth on the risk of autism: a 
nationwide register-based study. J. Child Psychol. Psychiatry, 46(9), 963--971 (2005) 
  
61. A. Reichenberg, R. Gross, M. Weiser, M. Bresnahan, J. Silverman, S. Harlap, J. Rabinowitz, C. Shulman, D. Malaspina, G. 
Lubin, H. Y. Knobler, M. Davidson and E. Susser: Advancing paternal age and autism. Arch. Gen. Psychiatry, 63(9), 1026--1032 
(2006) 
  
62. K. J. Tsuchiya, S. Takagai, M. Kawai, H. Matsumoto, K. Nakamura, Y. Minabe, N. Mori and N. Takei: Advanced paternal 
age associated with an elevated risk for schizophrenia in offspring in a Japanese population. Schizophr. Res., 76(2-3), 337--342 
(2005) 
  
63. M. D. Alter, R. Kharkar, K. E. Ramsey, D. W. Craig, R. D. Melmed, T. A. Grebe, R. C. Bay, S. Ober-Reynolds, J. Kirwan, J. 
J. Jones, J. B. Turner, R. Hen and D. A. Stephan: Autism and Increased Paternal Age Related Changes in Global Levels of Gene 
Expression Regulation. PLoS One, 6(2) (2011) 
  
64. C. M. Hultman, S. Sandin, S. Z. Levine, P. Lichtenstein and A. Reichenberg: Advancing paternal age and risk of autism: new 
evidence from a population-based study and a meta-analysis of epidemiological studies. Mol. Psychiatry, 16(12), 1203--1212 
(2011) 
  
14 
 
 
65. A. Kong, M. L. Frigge, G. Masson, S. Besenbacher, P. Sulem, G. Magnusson, S. A. Gudjonsson, A. Sigurdsson, A. 
Jonasdottir, A. Jonasdottir, W. Wong, G. Sigurdsson, G. B. Walters, S. Steinberg, H. Helgason, G. Thorleifsson, D. F. 
Gudbjartsson, A. Helgason, O. T. Magnusson, U. Thorsteinsdottir and K. Stefansson: Rate of de novo mutations, father’s age, 
and disease risk. Nature, 488(7412), 471 (2012) 
  
66. I. D. C. van Balkom, M. Bresnahan, P. J. Vuijk, J. Hubert, E. Susser and H. W. Hoek: Paternal Age and Risk of Autism in an 
Ethnically Diverse, Non-Industrialized Setting: Aruba. PLoS One, 7(9) (2012) 
  
67. X. Zhang, C.-C. Lv, J. Tian, R.-J. Miao, W. Xi, I. Hertz-Picciotto and L. Qi: Prenatal and perinatal risk factors for autism in 
China. J. Autism Dev. Disord., 40(11), 1311--1321 (2010) 
  
68. R. Sasanfar, S. A. Haddad, A. Tolouei, M. Ghadami, D. Yu and S. L. Santangelo: Paternal age increases the risk for autism in 
an Iranian population sample. Mol. Autism, 1(1), 2 (2010) 
  
69. M. Janecka, J. Mill, M. A. Basson, A. Goriely, H. Spiers, A. Reichenberg, L. Schalkwyk and C. Fernandes: Advanced 
paternal age effects in neurodevelopmental disorders—review of potential underlying mechanisms. Transl. Psychiatry, 7(1), 
e1019 (2017) 
  
70. A. Kolevzon, R. Gross and A. Reichenberg: Prenatal and perinatal risk factors for autism: a review and integration of 
findings. Arch. Pediatr. Adolesc. Med., 161(4), 326--333 (2007) 
  
71. A. N. Rosenthal and S. Paterson-Brown: Is there an incremental rise in the risk of obstetric intervention with increasing 
maternal age? Br. J. Obstet. Gynaecol., 105(10), 1064--1069 (1998)  
  
72. S. Sandin, C. M. Hultman, A. Kolevzon, R. Gross, J. H. MacCabe and A. Reichenberg: Advancing maternal age is associated 
with increasing risk for autism: a review and meta-analysis. J. Am. Acad. Child Adolesc. Psychiatry, 51(5), 477--4861 (2012) 
  
73. C. M. Hultman and P. Sparén: Autism--prenatal insults or an epiphenomenon of a strongly genetic disorder? Lancet, -
13;364(9433), 485--487 (2004) 
  
74. A. I. Eidelman and A. Samueloff: The pathophysiology of the fetus of the diabetic mother. Semin. Perinatol., 26(3), 232--236 
(2002)  
  
75. P. Krakowiak, C. K. Walker, A. A. Bremer, A. S. Baker, S. Ozonoff, R. L. Hansen and I. Hertz-Picciotto: Maternal Metabolic 
Conditions and Risk for Autism and Other Neurodevelopmental Disorders. Pediatrics, 129(5), e1121 (2012) 
  
76. V. Guinchat, P. Thorsen, C. Laurent, C. Cans, N. Bodeau and D. Cohen: Pre-, peri- and neonatal risk factors for autism. Acta 
Obstet. Gynecol. Scand., 91(3), 287--300 (2012)  
  
77. S.-C. Wang, B. Oelze and A. Schumacher: Age-Specific Epigenetic Drift in Late-Onset Alzheimer's Disease. PLoS One, 3(7) 
(2008) 
  
78. M. K. Georgieff: The effect of maternal diabetes during pregnancy on the neurodevelopment of offspring. Minn. Med., 89(3), 
44--47 (2006)  
  
79. E. Y. Deykin and B. Macmahon: VIRAL EXPOSURE AND AUTISM. aje., 109(6), 628--638 (1979) 
  
80. J. E. Libbey, T. L. Sweeten, W. M. McMahon and R. S. Fujinami: Autistic disorder and viral infections. J. Neurovirol., 11(1), 
1--10 (2005) 
  
81. E. A. London: The environment as an etiologic factor in autism: a new direction for research. Environ. Health Perspect., 
108(Suppl 3), 401 (2000) 
  
82. A. Ornoy, L. Weinstein-Fudim and Z. Ergaz: Prenatal factors associated with autism spectrum disorder (ASD). Reprod. 
Toxicol., 56, 155--69 (2015) 
  
83. H. Ó. Atladóttir, T. B. Henriksen, D. E. Schendel and E. T. Parner: Autism After Infection, Febrile Episodes, and Antibiotic 
Use During Pregnancy: An Exploratory Study. Pediatrics, 130(6), e1447 (2012) 
  
84. P. Moss: The Biology of the Autistic Syndromes, 3rd Edition. Canadian child and adolescent psychiatry review, 12(3), 97 
(2003)  
  
15 
 
 
85. Y. Yamashita, C. Fujimoto, E. Nakajima, T. Isagai and T. Matsuishi: Possible association between congenital 
cytomegalovirus infection and autistic disorder. J. Autism Dev. Disord., 33(4), 455--459 (2003)  
  
86. L. A. Croen, J. K. Grether, C. K. Yoshida, R. Odouli and J. Van de Water: Maternal autoimmune diseases, asthma and 
allergies, and childhood autism spectrum disorders: a case-control study. Arch. Pediatr. Adolesc. Med., 159(2), 151--157 (2005) 
  
87. M. A. Elovitz, A. G. Brown, K. Breen, L. Anton, M. Maubert and I. Burd: Intrauterine inflammation, insufficient to induce 
parturition, still evokes fetal and neonatal brain injury. Int J Dev Neurosci., 29(6), 663 (2011) 
  
88. S. Bölte, S. Knecht and F. Poustka: A case-control study of personality style and psychopathology in parents of subjects with 
autism. J. Autism Dev. Disord., 37(2), 243--250 (2007) 
  
89. B. Fish, J. Marcus, S. L. Hans, J. G. Auerbach and S. Perdue: Infants at risk for schizophrenia: sequelae of a genetic 
neurointegrative defect. A review and replication analysis of pandysmaturation in the Jerusalem Infant Development Study. Arch. 
Gen. Psychiatry, 49(3), 221--235 (1992)  
  
90. J. L. Daniels, U. Forssen, C. M. Hultman, S. Cnattingius, D. A. Savitz, M. Feychting and P. Sparen: Parental psychiatric 
disorders associated with autism spectrum disorders in the offspring. Pediatrics, 121(5), 1357--1362 (2008) 
  
91. S. Wolff, S. Narayan and B. Moyes: Personality characteristics of parents of autistic children: a controlled study. J. Child 
Psychol. Psychiatry, 29(2), 143--153 (1988)  
  
92. K. Gudsnuk and F. A. Champagne: Epigenetic Influence of Stress and the Social Environment. ILAR Journal, 53(3-4), 279 
(2012) 
  
93. C. O. Ladd, R. L. Huot, K. V. Thrivikraman, C. B. Nemeroff and P. M. Plotsky: Long-term adaptations in glucocorticoid 
receptor and mineralocorticoid receptor mRNA and negative feedback on the hypothalamo-pituitary-adrenal axis following 
neonatal maternal separation. Biol. Psychiatry, 55(4), 367--375 (2004) 
  
94. S. Maccari, M. Darnaudery, S. Morley-Fletcher, A. R. Zuena, C. Cinque and O. Van Reeth: Prenatal stress and long-term 
consequences: implications of glucocorticoid hormones. Neurosci. Biobehav. Rev., 27(1-2), 119--127 (2003)  
  
95. B. R. Mueller and T. L. Bale: Sex-Specific Programming of Offspring Emotionality Following Stress Early in Pregnancy. 
Journal of neuroscience : the official journal of the Society for Neuroscience, 28(36), 9055 (2008) 
  
96. K. O'Donnell, T. G. O'Connor and V. Glover: Prenatal stress and neurodevelopment of the child: focus on the HPA axis and 
role of the placenta. Dev. Neurosci., 31(4), 285--292 (2009) 
  
97. M. Weinstock: The long-term behavioural consequences of prenatal stress. Neurosci. Biobehav. Rev., 32(6), 1073--1086 
(2008) 
  
98. F. Perera and J. Herbstman: Prenatal environmental exposures, epigenetics, and disease. Reprod. Toxicol., 31(3), 363--373 
(2011) 
  
99. D. Q. Beversdorf, S. E. Manning, A. Hillier, S. L. Anderson, R. E. Nordgren, S. E. Walters, H. N. Nagaraja, W. C. Cooley, S. 
E. Gaelic and M. L. Bauman: Timing of prenatal stressors and autism. J. Autism Dev. Disord., 35(4), 471--478 (2005) 
  
100. C. M. Shivers, L. K. Deisenroth and J. L. Taylor: Patterns and Predictors of Anxiety among Siblings of Children with 
Autism Spectrum Disorders. J Autism Dev Disord., 43(6), 1336 (2013) 
  
101. M. Narita, A. Oyabu, Y. Imura, N. Kamada, T. Yokoyama, K. Tano, A. Uchida and N. Narita: Nonexploratory movement 
and behavioral alterations in a thalidomide or valproic acid-induced autism model rat. Neurosci. Res., 66(1), 2--6 (2010) 
  
102. A. Ornoy: Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod. Toxicol., 28(1), 1--10 
(2009) 
  
103. A. Z. Bauer and D. Kriebel: Prenatal and perinatal analgesic exposure and autism: an ecological link. Environ Health., 12, 
41 (2013) 
  
104. N. B. Gidaya, B. K. Lee, I. Burstyn, M. Yudell, E. L. Mortensen and C. J. Newschaffer: In utero exposure to selective 
serotonin reuptake inhibitors and risk for autism spectrum disorder. J. Autism Dev. Disord., 44(10), 2558--2567 (2014) 
  
16 
 
 
105. R. A. Harrington, L.-C. Lee, R. M. Crum, A. W. Zimmerman and I. Hertz-Picciotto: Prenatal SSRI use and offspring with 
autism spectrum disorder or developmental delay. Pediatrics, 133(5), 1241--1248 (2014) 
  
106. D. Rai, B. K. Lee, C. Dalman, J. Golding, G. Lewis and C. Magnusson: Parental depression, maternal antidepressant use 
during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ, 346 (2013) 
  
107. T. Ito, H. Ando, T. Suzuki, T. Ogura, K. Hotta, Y. Imamura, Y. Yamaguchi and H. Handa: Identification of a primary target 
of thalidomide teratogenicity. Science, 327(5971), 1345--1350 (2010) 
  
108. J. M. Bandim, L. O. Ventura, M. T. Miller, H. C. Almeida and A. E. S. Costa: Autism and Möbius sequence: an exploratory 
study of children in northeastern Brazil. Arq. Neuropsiquiatr., 61(2A), 181--185 (2003)  
  
109. F. R. Witter, A. W. Zimmerman, J. P. Reichmann and S. L. Connors: In utero beta 2 adrenergic agonist exposure and 
adverse neurophysiologic and behavioral outcomes. Am. J. Obstet. Gynecol., 201(6), 553--559 (2009) 
  
110. M. C. Zerrate, M. Pletnikov, S. L. Connors, D. L. Vargas, F. J. Seidler, A. W. Zimmerman, T. A. Slotkin and C. A. Pardo: 
Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism. J. 
Pharmacol. Exp. Ther., 322(1), 16--22 (2007) 
  
111. L.-C. Lee, R. A. Harrington, B. B. Louie and C. J. Newschaffer: Children with autism: quality of life and parental concerns. 
J. Autism Dev. Disord., 38(6), 1147--1160 (2008) 
  
112. N. E. Adler and K. Newman: Socioeconomic disparities in health: pathways and policies. Health Aff. (Millwood). 21(2), 60--
76 (2002) 
  
113. M. S. Durkin, M. J. Maenner, F. J. Meaney, S. E. Levy, C. DiGuiseppi, J. S. Nicholas, R. S. Kirby, J. A. Pinto-Martin and L. 
A. Schieve: Socioeconomic Inequality in the Prevalence of Autism Spectrum Disorder: Evidence from a U.S. Cross-Sectional 
Study. PLoS One, 5(7) (2010) 
  
114. J. A. Finegan and B. Quarrington: Pre-, peri-, and neonatal factors and infantile autism. J. Child Psychol. Psychiatry, 20(2), 
119--128 (1979)  
  
115. A. T. Kaczynski and K. A. Henderson: Parks and recreation settings and active living: a review of associations with physical 
activity function and intensity. J. Phys. Act. Health, 5(4), 619--632 (2008)  
  
116. S. A. Samadi and R. McConkey: Autism in developing countries: lessons from iran. Autism Res. Treat., 2011, 145359 
(2011) 
  
117. L. A. Croen, J. K. Grether and S. Selvin: Descriptive epidemiology of autism in a California population: who is at risk? J. 
Autism Dev. Disord., 32(3), 217--224 (2002)  
  
118. D. Hvidtjørn, J. Grove, D. Schendel, L. A. Schieve, C. Sværke, E. Ernst and P. Thorsen: Risk of autism spectrum disorders 
in children born after assisted conception: a population-based follow-up study. J. Epidemiol. Community Health, 65(6), 497--502 
(2011) 
  
119. M. D. King and P. S. Bearman: Socioeconomic Status and the Increased Prevalence of Autism in California. Am. Sociol. 
Rev., 76(2), 320--346 (2011) 
  
120. S. Buchmayer, S. Johansson, A. Johansson, C. M. Hultman, P. Sparén and S. Cnattingius: Can association between preterm 
birth and autism be explained by maternal or neonatal morbidity? Pediatrics, 124(5), 817--825 (2009) 
  
121. R. D. Maimburg and M. Vaeth: Perinatal risk factors and infantile autism. Acta Psychiatr. Scand., 114(4), 257--264 (2006) 
  
122. F. H. Previc: Prenatal influences on brain dopamine and their relevance to the rising incidence of autism. Med. Hypotheses, 
68(1), 46--60 (2006) 
  
123. W. W. Eaton, P. B. Mortensen, P. H. Thomsen and M. Frydenberg: Obstetric complications and risk for severe 
psychopathology in childhood. J. Autism Dev. Disord., 31(3), 279--285 (2001)  
  
124. R. D. Maimburg, B. H. Bech, M. Vaeth, B. Møller-Madsen and J. Olsen: Neonatal jaundice, autism, and other disorders of 
psychological development. Pediatrics, 126(5), 872--878 (2010) 
  
17 
 
 
125. R. D. Maimburg, M. Vaeth, D. E. Schendel, B. H. Bech, J. Olsen and P. Thorsen: Neonatal jaundice: a risk factor for 
infantile autism? Paediatr. Perinat. Epidemiol., 22(6), 562--568 (2008) 
  
126. C. J. Newschaffer, D. Fallin and N. L. Lee: Heritable and nonheritable risk factors for autism spectrum disorders. Epidemiol. 
Rev., 24(2), 137--153 (2002) 
  
127. N. J. Rosen, C. K. Yoshida and L. A. Croen: Infection in the first 2 years of life and autism spectrum disorders. Pediatrics, 
119(1), 61--69 (2007) 
  
128. Q. Li, C. Cheung, R. Wei, E. S. Hui, J. Feldon, U. Meyer, S. Chung, S. E. Chua, P. C. Sham, E. X. Wu and G. M. 
McAlonan: Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant to schizophrenia: 
evidence from MRI in a mouse model. PLoS One, 4(7), e6354 (2009) 
  
129. L. Kanner: Autistic disturbances of affective contact. Nervous Child. In,  (1943)  
  
130. W. H. Organization: Pervasive developmental disorders. In international statistical classification of diseases and related 
health Problems, 10th revision. In,  (2016)  
  
131. American Psychiatric Association.: Autism spectrum disorder. In Diagnostic and statistical manual of mental disorders (5th 
ed.). In, (2013)  
  
132. D. Robins, D. Fein and M. Barton: Modified Checklist for Autism in Toddlers, Revised with Follow-Up. In,  (2009)  
  
133. A. Baghdadli, F. Russet and L. Mottron: Measurement properties of screening and diagnostic tools for autism spectrum 
adults of mean normal intelligence: A systematic review. Eur Psychiatry, 44, 104-124 (2017) 
  
134. T. W. Frazier, E. W. Klingemier, M. Beukemann, L. Speer, L. Markowitz, S. Parikh, S. Wexberg, K. Giuliano, E. Schulte, 
C. Delahunty, V. Ahuja, C. Eng, M. J. Manos, A. Y. Hardan, E. A. Youngstrom and M. S. Strauss: Development of an Objective 
Autism Risk Index Using Remote Eye Tracking. J. Am. Acad. Child Adolesc. Psychiatry, 55(4), 301-309 (2016) 
  
135. Autism Speaks, www.autismspeaks.org (Retrieved May 6, 2018)  
  
136. Microsoft: Microsoft Autism Hiring Program. (Retrieved May 6, 2018)  
  
137. L. H. Waterhouse: Rethinking autism: variation and complexity. Academic Press, London; Waltham, MA (2013)  
  
138. A. Posar, F. Resca and P. Visconti: Autism according to diagnostic and statistical manual of mental disorders 5(th) edition: 
The need for further improvements. J Pediatr Neurosci, 10(2), 146-8 (2015) 
  
139. Simons Foundation, www.simonsfoundation.org (Retrieved May 6, 2018)  
  
140. J. Cotney, R. A. Muhle, S. J. Sanders, L. Liu, A. J. Willsey, W. Niu, W. Liu, L. Klei, J. Lei, J. Yin, S. K. Reilly, A. T. 
Tebbenkamp, C. Bichsel, M. Pletikos, N. Sestan, K. Roeder, M. W. State, B. Devlin and J. P. Noonan: The autism-associated 
chromatin modifier CHD8 regulates other autism risk genes during human neurodevelopment. Nat. Commun., 6, 6404 (2015) 
  
141. A. Sugathan, M. Biagioli, C. Golzio, S. Erdin, I. Blumenthal, P. Manavalan, A. Ragavendran, H. Brand, D. Lucente, J. 
Miles, S. D. Sheridan, A. Stortchevoi, M. Kellis, S. J. Haggarty, N. Katsanis, J. F. Gusella and M. E. Talkowski: CHD8 regulates 
neurodevelopmental pathways associated with autism spectrum disorder in neural progenitors. PNAS, 111(42), 4468--4477 
(2014) 
  
142. S. S. Jeste, J. Frohlich and S. K. Loo: Electrophysiological biomarkers of diagnosis and outcome in neurodevelopmental 
disorders. Curr. Opin. Neurol., 28(2), 110--116 (2015) 
  
143. M. Benger, M. Kinali and N. D. Mazarakis: Autism spectrum disorder: prospects for treatment using gene therapy. 
Molecular Autism, 9 (2018) 
  
144. J. J. Lee, R. Wedow, A. Okbay, E. Kong, O. Maghzian, M. Zacher, T. A. Nguyen-Viet, P. Bowers, J. Sidorenko, R. 
Karlsson Linnér, M. A. Fontana, T. Kundu, C. Lee, H. Li, R. Li, R. Royer, P. N. Timshel, R. K. Walters, E. A. Willoughby, L. 
Yengo, M. Alver, Y. Bao, D. W. Clark, F. R. Day, N. A. Furlotte, P. K. Joshi, K. E. Kemper, A. Kleinman, C. Langenberg, R. 
Mägi, J. W. Trampush, S. S. Verma, Y. Wu, M. Lam, J. H. Zhao, Z. Zheng, J. D. Boardman, H. Campbell, J. Freese, K. M. 
Harris, C. Hayward, P. Herd, M. Kumari, T. Lencz, J. a. Luan, A. K. Malhotra, A. Metspalu, L. Milani, K. K. Ong, J. R. B. Perry, 
D. J. Porteous, M. D. Ritchie, M. C. Smart, B. H. Smith, J. Y. Tung, N. J. Wareham, J. F. Wilson, J. P. Beauchamp, D. C. 
18 
 
 
Conley, T. Esko, S. F. Lehrer, P. K. E. Magnusson, S. Oskarsson, T. H. Pers, M. R. Robinson, K. Thom, C. Watson, C. F. 
Chabris, M. N. Meyer, D. I. Laibson, J. Yang, M. Johannesson, P. D. Koellinger, P. Turley, P. M. Visscher, D. J. Benjamin and 
D. Cesarini: Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 
million individuals. Nat. Genet., 50(8), 1112--1121 (2018) 
  
145. Le Couteur, A., Lord, C., and Rutter, M. Autism Diagnostic Interview-Revised (ADI-R) Los Angeles: Western 
Psychological Services, (2003) 
  
146. J. Gilliam: GARS-2: Gilliam Autism Rating Scale-Second Edition. (2006)  
  
147. E. Schopler: (CARS-2) Childhood Autism Rating Scale, Second Edition. In: Ed M. E. Van Bourgondien. (2010)  
  
148. D. Kim, H. Volk, S. Girirajan, S. Pendergrass, M. A. Hall, S. S. Verma, R. J. Schmidt, R. L. Hansen, D. Ghosh, Y. Ludena-
Rodriguez, K. Kim, M. D. Ritchie, I. Hertz-Picciotto and S. B. Selleck: The joint effect of air pollution exposure and copy 
number variation on risk for autism. Autism Res, 10(9), 1470-1480 (2017) 
  
149. R. J. Schmidt, V. Kogan, J. F. Shelton, L. Delwiche, R. L. Hansen, S. Ozonoff, C. C. Ma, E. C. McCanlies, D. H. Bennett, I. 
Hertz-Picciotto, D. J. Tancredi and H. E. Volk: Combined Prenatal Pesticide Exposure and Folic Acid Intake in Relation to 
Autism Spectrum Disorder. Environ Health Perspect, 125(9), 097007 (2017) 
  
150. G. C. Sharp, L. A. Salas, C. Monnereau, C. Allard, P. Yousefi, T. M. Everson, J. Bohlin, Z. Xu, R. C. Huang, S. E. Reese, 
C. J. Xu, N. Baïz, C. Hoyo, G. Agha, R. Roy, J. W. Holloway, A. Ghantous, S. K. Merid, K. M. Bakulski, L. K. Küpers, H. 
Zhang, R. C. Richmond, C. M. Page, L. Duijts, R. T. Lie, P. E. Melton, J. M. Vonk, E. A. Nohr, C. Williams-DeVane, K. Huen, 
S. L. Rifas-Shiman, C. Ruiz-Arenas, S. Gonseth, F. I. Rezwan, Z. Herceg, S. Ekström, L. Croen, F. Falahi, P. Perron, M. R. 
Karagas, B. M. Quraishi, M. Suderman, M. C. Magnus, V. W. V. Jaddoe, J. A. Taylor, D. Anderson, S. Zhao, H. A. Smit, M. J. 
Josey, A. Bradman, A. A. Baccarelli, M. Bustamante, S. E. Håberg, G. Pershagen, I. Hertz-Picciotto, C. Newschaffer, E. 
Corpeleijn, L. Bouchard, D. A. Lawlor, R. L. Maguire, L. F. Barcellos, G. Davey Smith, B. Eskenazi, W. Karmaus, C. J. Marsit, 
M. F. Hivert, H. Snieder, M. D. Fallin, E. Melén, M. C. Munthe-Kaas, H. Arshad, J. L. Wiemels, I. Annesi-Maesano, M. 
Vrijheid, E. Oken, N. Holland, S. K. Murphy, T. I. A. Sørensen, G. H. Koppelman, J. P. Newnham, A. J. Wilcox, W. Nystad, S. 
J. London, J. F. Felix and C. L. Relton: Maternal BMI at the start of pregnancy and offspring epigenome-wide DNA methylation: 
findings from the pregnancy and childhood epigenetics (PACE) consortium. Hum Mol Genet, 26(20), 4067-4085 (2017) 
  
151. Y. M. Al-Farsi, M. M. Al-Sharbati, M. I. Waly, O. A. Al-Farsi, M. A. Al-Shafaee, M. M. Al-Khaduri, M. S. Trivedi and R. 
C. Deth: Effect of suboptimal breast-feeding on occurrence of autism: a case-control study. Nutrition, 28(7-8), e27-32 (2012) 
  
152. L. A. Weiss, D. E. Arking, H. Gene Discovery Project of Johns, C. the Autism, M. J. Daly and A. Chakravarti: A genome-
wide linkage and association scan reveals novel loci for autism. Nature, 461(7265), 802-8 (2009) 
  
153. M. Alarcon, B. S. Abrahams, J. L. Stone, J. A. Duvall, J. V. Perederiy, J. M. Bomar, J. Sebat, M. Wigler, C. L. Martin, D. H. 
Ledbetter, S. F. Nelson, R. M. Cantor and D. H. Geschwind: Linkage, association, and gene-expression analyses identify 
CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet, 82(1), 150-9 (2008) 
  
154. J. K. Lowe, D. M. Werling, J. N. Constantino, R. M. Cantor and D. H. Geschwind: Social responsiveness, an autism 
endophenotype: genomewide significant linkage to two regions on chromosome 8. Am J Psychiatry, 172(3), 266-75 (2015) 
  
155. D. H. Geschwind: Autism: many genes, common pathways? Cell, 135(3), 391-5 (2008) 
  
156. K. Wang, H. Zhang, D. Ma, M. Bucan, J. T. Glessner, B. S. Abrahams, D. Salyakina, M. Imielinski, J. P. Bradfield, P. M. 
Sleiman, C. E. Kim, C. Hou, E. Frackelton, R. Chiavacci, N. Takahashi, T. Sakurai, E. Rappaport, C. M. Lajonchere, J. Munson, 
A. Estes, O. Korvatska, J. Piven, L. I. Sonnenblick, A. I. Alvarez Retuerto, E. I. Herman, H. Dong, T. Hutman, M. Sigman, S. 
Ozonoff, A. Klin, T. Owley, J. A. Sweeney, C. W. Brune, R. M. Cantor, R. Bernier, J. R. Gilbert, M. L. Cuccaro, W. M. 
McMahon, J. Miller, M. W. State, T. H. Wassink, H. Coon, S. E. Levy, R. T. Schultz, J. I. Nurnberger, J. L. Haines, J. S. 
Sutcliffe, E. H. Cook, N. J. Minshew, J. D. Buxbaum, G. Dawson, S. F. Grant, D. H. Geschwind, M. A. Pericak-Vance, G. D. 
Schellenberg and H. Hakonarson: Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature, 
459(7246), 528-33 (2009) 
  
157. S. Jamain, H. Quach, C. Betancur, M. Rastam, C. Colineaux, I. C. Gillberg, H. Soderstrom, B. Giros, M. Leboyer, C. 
Gillberg, T. Bourgeron and S. Paris Autism Research International Sibpair: Mutations of the X-linked genes encoding neuroligins 
NLGN3 and NLGN4 are associated with autism. Nat Genet, 34(1), 27-9 (2003) 
  
19 
 
 
158. K. A. Strauss, E. G. Puffenberger, M. J. Huentelman, S. Gottlieb, S. E. Dobrin, J. M. Parod, D. A. Stephan and D. H. 
Morton: Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med, 354(13), 1370-7 
(2006) 
  
159. E. M. Morrow, S. Y. Yoo, S. W. Flavell, T. K. Kim, Y. Lin, R. S. Hill, N. M. Mukaddes, S. Balkhy, G. Gascon, A. Hashmi, 
S. Al-Saad, J. Ware, R. M. Joseph, R. Greenblatt, D. Gleason, J. A. Ertelt, K. A. Apse, A. Bodell, J. N. Partlow, B. Barry, H. 
Yao, K. Markianos, R. J. Ferland, M. E. Greenberg and C. A. Walsh: Identifying autism loci and genes by tracing recent shared 
ancestry. Science, 321(5886), 218-23 (2008) 
  
160. G. Novarino, P. El-Fishawy, H. Kayserili, N. A. Meguid, E. M. Scott, J. Schroth, J. L. Silhavy, M. Kara, R. O. Khalil, T. 
Ben-Omran, A. G. Ercan-Sencicek, A. F. Hashish, S. J. Sanders, A. R. Gupta, H. S. Hashem, D. Matern, S. Gabriel, L. 
Sweetman, Y. Rahimi, R. A. Harris, M. W. State and J. G. Gleeson: Mutations in BCKD-kinase lead to a potentially treatable 
form of autism with epilepsy. Science, 338(6105), 394-7 (2012) 
  
161. R. Moessner, C. R. Marshall, J. S. Sutcliffe, J. Skaug, D. Pinto, J. Vincent, L. Zwaigenbaum, B. Fernandez, W. Roberts, P. 
Szatmari and S. W. Scherer: Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet, 81(6), 1289-97 
(2007) 
  
162. H. G. Kim, S. Kishikawa, A. W. Higgins, I. S. Seong, D. J. Donovan, Y. Shen, E. Lally, L. A. Weiss, J. Najm, K. Kutsche, 
M. Descartes, L. Holt, S. Braddock, R. Troxell, L. Kaplan, F. Volkmar, A. Klin, K. Tsatsanis, D. J. Harris, I. Noens, D. L. Pauls, 
M. J. Daly, M. E. MacDonald, C. C. Morton, B. J. Quade and J. F. Gusella: Disruption of neurexin 1 associated with autism 
spectrum disorder. Am J Hum Genet, 82(1), 199-207 (2008) 
  
163. S. Berkel, C. R. Marshall, B. Weiss, J. Howe, R. Roeth, U. Moog, V. Endris, W. Roberts, P. Szatmari, D. Pinto, M. Bonin, 
A. Riess, H. Engels, R. Sprengel, S. W. Scherer and G. A. Rappold: Mutations in the SHANK2 synaptic scaffolding gene in 
autism spectrum disorder and mental retardation. Nat Genet, 42(6), 489-91 (2010) 
  
164. S. Berkel, W. Tang, M. Trevino, M. Vogt, H. A. Obenhaus, P. Gass, S. W. Scherer, R. Sprengel, G. Schratt and G. A. 
Rappold: Inherited and de novo SHANK2 variants associated with autism spectrum disorder impair neuronal morphogenesis and 
physiology. Hum Mol Genet, 21(2), 344-57 (2012) 
  
165. D. Sato, A. C. Lionel, C. S. Leblond, A. Prasad, D. Pinto, S. Walker, I. O'Connor, C. Russell, I. E. Drmic, F. F. Hamdan, J. 
L. Michaud, V. Endris, R. Roeth, R. Delorme, G. Huguet, M. Leboyer, M. Rastam, C. Gillberg, M. Lathrop, D. J. Stavropoulos, 
E. Anagnostou, R. Weksberg, E. Fombonne, L. Zwaigenbaum, B. A. Fernandez, W. Roberts, G. A. Rappold, C. R. Marshall, T. 
Bourgeron, P. Szatmari and S. W. Scherer: SHANK1 Deletions in Males with Autism Spectrum Disorder. Am J Hum Genet, 
90(5), 879-87 (2012) 
  
166. A. K. Vaags, A. C. Lionel, D. Sato, M. Goodenberger, Q. P. Stein, S. Curran, C. Ogilvie, J. W. Ahn, I. Drmic, L. Senman, 
C. Chrysler, A. Thompson, C. Russell, A. Prasad, S. Walker, D. Pinto, C. R. Marshall, D. J. Stavropoulos, L. Zwaigenbaum, B. 
A. Fernandez, E. Fombonne, P. F. Bolton, D. A. Collier, J. C. Hodge, W. Roberts, P. Szatmari and S. W. Scherer: Rare deletions 
at the neurexin 3 locus in autism spectrum disorder. Am J Hum Genet, 90(1), 133-41 (2012) 
  
167. C. Helsmoortel, A. T. Vulto-van Silfhout, B. P. Coe, G. Vandeweyer, L. Rooms, J. van den Ende, J. H. Schuurs-
Hoeijmakers, C. L. Marcelis, M. H. Willemsen, L. E. Vissers, H. G. Yntema, M. Bakshi, M. Wilson, K. T. Witherspoon, H. 
Malmgren, A. Nordgren, G. Anneren, M. Fichera, P. Bosco, C. Romano, B. B. de Vries, T. Kleefstra, R. F. Kooy, E. E. Eichler 
and N. Van der Aa: A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. Nat Genet, 46(4), 380-4 (2014) 
  
168. E. T. Lim, S. Raychaudhuri, S. J. Sanders, C. Stevens, A. Sabo, D. G. MacArthur, B. M. Neale, A. Kirby, D. M. Ruderfer, 
M. Fromer, M. Lek, L. Liu, J. Flannick, S. Ripke, U. Nagaswamy, D. Muzny, J. G. Reid, A. Hawes, I. Newsham, Y. Wu, L. 
Lewis, H. Dinh, S. Gross, L. S. Wang, C. F. Lin, O. Valladares, S. B. Gabriel, M. dePristo, D. M. Altshuler, S. M. Purcell, N. E. 
S. Project, M. W. State, E. Boerwinkle, J. D. Buxbaum, E. H. Cook, R. A. Gibbs, G. D. Schellenberg, J. S. Sutcliffe, B. Devlin, 
K. Roeder and M. J. Daly: Rare complete knockouts in humans: population distribution and significant role in autism spectrum 
disorders. Neuron, 77(2), 235-42 (2013) 
  
169. N. Krumm, T. N. Turner, C. Baker, L. Vives, K. Mohajeri, K. Witherspoon, A. Raja, B. P. Coe, H. A. Stessman, Z. X. He, 
S. M. Leal, R. Bernier and E. E. Eichler: Excess of rare, inherited truncating mutations in autism. Nat Genet, 47(6), 582-8 (2015) 
  
170. W. H. Chien, S. S. Gau, C. H. Chen, W. C. Tsai, Y. Y. Wu, P. H. Chen, C. Y. Shang and C. H. Chen: Increased gene 
expression of FOXP1 in patients with autism spectrum disorders. Mol Autism, 4(1), 23 (2013) 
  
20 
 
 
171. S. Gupta, S. E. Ellis, F. N. Ashar, A. Moes, J. S. Bader, J. Zhan, A. B. West and D. E. Arking: Transcriptome analysis 
reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat Commun, 5, 5748 
(2014) 
  
172. Timothy W. Yu, Maria H. Chahrour, Michael E. Coulter, S. Jiralerspong, K. Okamura-Ikeda, B. Ataman, K. Schmitz-Abe, 
David A. Harmin, M. Adli, Athar N. Malik, Alissa M. D’Gama, Elaine T. Lim, Stephan J. Sanders, Ganesh H. Mochida, 
Jennifer N. Partlow, Christine M. Sunu, Jillian M. Felie, J. Rodriguez, Ramzi H. Nasir, J. Ware, Robert M. Joseph, R. S. Hill, 
Benjamin Y. Kwan, M. Al-Saffar, Nahit M. Mukaddes, A. Hashmi, S. Balkhy, Generoso G. Gascon, Fuki M. Hisama, E. LeClair, 
A. Poduri, O. Oner, S. Al-Saad, Sadika A. Al-Awadi, L. Bastaki, T. Ben-Omran, Ahmad S. Teebi, L. Al-Gazali, V. Eapen, 
Christine R. Stevens, L. Rappaport, Stacey B. Gabriel, K. Markianos, Matthew W. State, Michael E. Greenberg, H. Taniguchi, 
Nancy E. Braverman, Eric M. Morrow and Christopher A. Walsh: Using Whole-Exome Sequencing to Identify Inherited Causes 
of Autism. Neuron, 77(2), 259-273 (2013) 
  
173. T. N. Turner, F. Hormozdiari, M. H. Duyzend, S. A. McClymont, P. W. Hook, I. Iossifov, A. Raja, C. Baker, K. Hoekzema, 
H. A. Stessman, M. C. Zody, B. J. Nelson, J. Huddleston, R. Sandstrom, J. D. Smith, D. Hanna, J. M. Swanson, E. M. Faustman, 
M. J. Bamshad, J. Stamatoyannopoulos, D. A. Nickerson, A. S. McCallion, R. Darnell and E. E. Eichler: Genome Sequencing of 
Autism-Affected Families Reveals Disruption of Putative Noncoding Regulatory DNA. Am J Hum Genet, 98(1), 58-74 (2016) 
  
174. C. Ladd-Acosta, K. D. Hansen, E. Briem, M. D. Fallin, W. E. Kaufmann and A. P. Feinberg: Common DNA methylation 
alterations in multiple brain regions in autism. Mol Psychiatry, 19(8), 862-71 (2014) 
  
175. S. Nardone, D. S. Sams, E. Reuveni, D. Getselter, O. Oron, M. Karpuj and E. Elliott: DNA methylation analysis of the 
autistic brain reveals multiple dysregulated biological pathways. Transl Psychiatry, 4, e433 (2014) 
  
176. J. M. Lasalle: Autism genes keep turning up chromatin. OA Autism, 1(2), 14 (2013)  
  
177. D. LoParo and I. D. Waldman: The oxytocin receptor gene (OXTR) is associated with autism spectrum disorder: a meta-
analysis. Mol Psychiatry, 20(5), 640-6 (2015) 
  
178. A. Zhubi, Y. Chen, E. Dong, E. H. Cook, A. Guidotti and D. R. Grayson: Increased binding of MeCP2 to the GAD1 and 
RELN promoters may be mediated by an enrichment of 5-hmC in autism spectrum disorder (ASD) cerebellum. Transl 
Psychiatry, 4, e349 (2014) 
  
179. S. J. James, S. Shpyleva, S. Melnyk, O. Pavliv and I. P. Pogribny: Complex epigenetic regulation of engrailed-2 (EN-2) 
homeobox gene in the autism cerebellum. Transl Psychiatry, 3, e232 (2013) 
  
180. S. J. James, S. Shpyleva, S. Melnyk, O. Pavliv and I. P. Pogribny: Elevated 5-hydroxymethylcytosine in the Engrailed-2 
(EN-2) promoter is associated with increased gene expression and decreased MeCP2 binding in autism cerebellum. Transl 
Psychiatry, 4, e460 (2014) 
  
181. E. R. Berko, M. Suzuki, F. Beren, C. Lemetre, C. M. Alaimo, R. B. Calder, K. Ballaban-Gil, B. Gounder, K. Kampf, J. 
Kirschen, S. B. Maqbool, Z. Momin, D. M. Reynolds, N. Russo, L. Shulman, E. Stasiek, J. Tozour, M. Valicenti-McDermott, S. 
Wang, B. S. Abrahams, J. Hargitai, D. Inbar, Z. Zhang, J. D. Buxbaum, S. Molholm, J. J. Foxe, R. W. Marion, A. Auton and J. 
M. Greally: Mosaic epigenetic dysregulation of ectodermal cells in autism spectrum disorder. PLoS Genet, 10(5), e1004402 
(2014) 
  
182. T. Kubota and K. Mochizuki: Epigenetic Effect of Environmental Factors on Autism Spectrum Disorders. Int J Environ Res 
Public Health, 13(5) (2016) 
  
183. M. Irimia, R. J. Weatheritt, J. D. Ellis, N. N. Parikshak, T. Gonatopoulos-Pournatzis, M. Babor, M. Quesnel-Vallieres, J. 
Tapial, B. Raj, D. O'Hanlon, M. Barrios-Rodiles, M. J. Sternberg, S. P. Cordes, F. P. Roth, J. L. Wrana, D. H. Geschwind and B. 
J. Blencowe: A highly conserved program of neuronal microexons is misregulated in autistic brains. Cell, 159(7), 1511-23 (2014) 
  
184. M. Quesnel-Vallieres, Z. Dargaei, M. Irimia, T. Gonatopoulos-Pournatzis, J. Y. Ip, M. Wu, T. Sterne-Weiler, S. Nakagawa, 
M. A. Woodin, B. J. Blencowe and S. P. Cordes: Misregulation of an Activity-Dependent Splicing Network as a Common 
Mechanism Underlying Autism Spectrum Disorders. Mol Cell, 64(6), 1023-1034 (2016) 
  
185. A. Vogel-Ciernia and M. A. Wood: Neuron-specific chromatin remodeling: a missing link in epigenetic mechanisms 
underlying synaptic plasticity, memory, and intellectual disability disorders. Neuropharmacology, 80, 18-27 (2014) 
  
186. A. J. Lopez and M. A. Wood: Role of nucleosome remodeling in neurodevelopmental and intellectual disability disorders. 
Front Behav Neurosci, 9, 100 (2015) 
21 
 
 
  
187. B. L. Gudenas, A. K. Srivastava and L. Wang: Integrative genomic analyses for identification and prioritization of long non-
coding RNAs associated with autism. PLoS One, 12(5), e0178532 (2017) 
  
188. J. Tang, Y. Yu and W. Yang: Long noncoding RNA and its contribution to autism spectrum disorders. CNS Neurosci Ther, 
23(8), 645-656 (2017) 
  
189. Y. Wang, X. Zhao, W. Ju, M. Flory, J. Zhong, S. Jiang, P. Wang, X. Dong, X. Tao, Q. Chen, C. Shen, M. Zhong, Y. Yu, W. 
T. Brown and N. Zhong: Genome-wide differential expression of synaptic long noncoding RNAs in autism spectrum disorder. 
Transl Psychiatry, 5, e660 (2015) 
  
190. J. J. DeWitt, N. Grepo, B. Wilkinson, O. V. Evgrafov, J. A. Knowles and D. B. Campbell: Impact of the Autism-Associated 
Long Noncoding RNA MSNP1AS on Neuronal Architecture and Gene Expression in Human Neural Progenitor Cells. Genes 
(Basel), 7(10) (2016) 
  
191. J. J. DeWitt, P. M. Hecht, N. Grepo, B. Wilkinson, O. V. Evgrafov, K. V. Morris, J. A. Knowles and D. B. Campbell: 
Transcriptional Gene Silencing of the Autism-Associated Long Noncoding RNA MSNP1AS in Human Neural Progenitor Cells. 
Dev Neurosci, 38(5), 375-383 (2016) 
  
192. S. M. Hammond: An overview of microRNAs. Adv Drug Deliv Rev, 87, 3-14 (2015) 
  
193. A. M. Mohr and J. L. Mott: Overview of microRNA biology. Semin Liver Dis, 35(1), 3-11 (2015) 
  
194. T. Sarachana, R. Zhou, G. Chen, H. K. Manji and V. W. Hu: Investigation of post-transcriptional gene regulatory networks 
associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med, 2(4), 
23 (2010) 
  
195. Y. E. Wu, N. N. Parikshak, T. G. Belgard and D. H. Geschwind: Genome-wide, integrative analysis implicates microRNA 
dysregulation in autism spectrum disorder. Nat Neurosci, 19(11), 1463-1476 (2016) 
  
196. C. Toma, B. Torrico, A. Hervas, M. Salgado, I. Rueda, R. Valdes-Mas, J. K. Buitelaar, N. Rommelse, B. Franke, C. Freitag, 
A. Reif, L. A. Perez-Jurado, A. Battaglia, L. Mazzone, E. Bacchelli, X. S. Puente and B. Cormand: Common and rare variants of 
microRNA genes in autism spectrum disorders. World J Biol Psychiatry, 1-11 (2015) 
  
197. A. M. Bond, M. J. Vangompel, E. A. Sametsky, M. F. Clark, J. C. Savage, J. F. Disterhoft and J. D. Kohtz: Balanced gene 
regulation by an embryonic brain ncRNA is critical for adult hippocampal GABA circuitry. Nat Neurosci, 12(8), 1020-7 (2009) 
  
198. L. Lipovich, F. Dachet, J. Cai, S. Bagla, K. Balan, H. Jia and J. A. Loeb: Activity-dependent human brain coding/noncoding 
gene regulatory networks. Genetics, 192(3), 1133-48 (2012) 
  
22 
 
 
 
Table 1. Postulated reasons for ASD increased prevalence  
The impact in measuring the prevalence of ASD 
• Awareness 
• Expanded diagnostic criteria (reclassification) 
• Diagnostic substitution 
• To qualify for support services 
• Reporting practices 
Based on references 5, 7, 19 
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Table 2. Factors associated with increased risk of ASD 
Most common comorbidities 
• Anxiety 
• Sleep disorders 
• Learning disability 
• Obsessive compulsive disorder 
• Developmental coordination disorder 
• Intellectual disability (50%) 
• ADHD 
• Sensory problems 
• Speech  
• Stereotypies 
• Epilepsy (25%) 
• Gastrointestinal problems 
• Immune disorders 
Rare genetic comorbidities 
• Tourette’s Syndrome 
• Tuberous Sclerosis 
• Fragile X 
• Rett's Syndrome 
• Fox 1 Gene 
• Timothy Syndrome 
Other risk factors for the development of ASD  
• In vitro fertilization  
• Prenatal exposure to air pollution 
• Prenatal exposure to medications: Valproate (anti-seizure)1, Thalidomide, Phthalates, Pesticides 
• Prenatal exposure to chemicals and plastics including PCBs and PBDEs 
• Pre-eclampsia 
• Gestational diabetes 
• Infections 
• Fever (late trimesters, without drug treatment) 
• Metabolic conditions 
• Obesity 
• Advanced maternal age due to increased risk of chromosomal abnormalities in ova of increased age or/and because of unstable trinucleotide repeats 
• Gestational hemorrhage by causing fetal hypoxia  
• Prenatal drug use (psychoactive drugs) 
• Prenatal stress 
• Maternal mental diseases 
• Maternal nutrition: folic acid, iron, fatty acids, vitamins 
• Paternal Age2 
• Interpregnancy Interval (time between pregnancies) 
• Prematurity and postmaturity 
• Twin birth 
• Suboptimal breast-feeding 
• Birth order 
• Familial socioeconmoic status  
• Infant gender 
• Ceserean delivery 
• Prenatal exposure to hypoxia  
• Congnital anomolies  
• Fetal respiratory distress 
• Post natal complications 
Based on references 1, 3, 8, 9, 148-151. 1The study by Hertz-Picciotto, Schmidt and Krakowiak (2018), found that prenatal 
exposure nearly tripled the risk of autism spectrum disorder (ASD). 2 De novo point mutations are overwhelmingly paternal in 
origin (4:1 bias) and positively correlated with advanced paternal age imprinted genes. 
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Table 3. Genetic factors increasing the risk of ASD 
Genetic risk factors for ASD Description of genetic factors Reference 
De novo large CNVs duplications, such as duplication of 15q, 
deletions of 22q11.2., deletion of Xp22.3., and duplication or 
deletion of 16p11.2. (∼600 kb, comprises around 29 genes), along 
of de novo submicroscopic CNVs such as duplication of 7q11.2.3. 
and microdeletion of 16p11.2. 
The structural chromosomal variations contribution is estimated 
to be between 15% and 25% and considered as are the underlying 
cause for many cases of ASD. 
(24, 37-44) 
De novo SNVs in DYRK1A, POGZ, CHD8, NTNG1, GRIN2B, 
KATNAL2, and SCN2A. 
These genes have a predominantly paternal origin and their 
frequency increases with paternal age. 
(45, 46) 
Regions/loci on chromosomes 20p13 and 7q35 (CNTNAP2) and 
two loci mapped on chromosome 8. 
Regions of genetic susceptibility, these loci are associated with 
speech delay and social responsiveness 
(152, 153) 
(154, 155) 
1-Intergenic variants between CDH9 and CDH10 on chromosome 
5p14.1 such as rs4307059, rs10513025, 
rs10513026, rs16883317, rs10065041, rs7704909 rs1896731 
rs10038113, rs6894838, rs12518194, rs4307059  
2- Variant within the MACROD2 gene on chromosome 20p12.1 
such as rs4141463 
 
3- Variants in the 5p15.2 such asrs10513025, rs10513026 and 
rs16883317 
 
4-variants on 1p13. 2 within candidate gene TRIM33 suh as 
rs936938, rs6537835 and rs1877455 
 
5- Variants in the DOCK4 IMMP2L and ZNF533 rs11885327, 
rs1964081, and rs2217262) that are associated with autism 
These are common variants in ASD. (44, 156) 
Neuroligin family NLGN3 and NLGN4 Rare X-linked mutations in ASD males and mental retardation in 
several families. 
(157) 
CNTNAP2, SLC9A9, BCKDK, AMT, PEX7, SYNE1, VPS13B, 
PAH, and POMGNT1  
Rare recessive mutations in consanguineous families were 
identified in Amish families as well as Middle Eastern families 
with ASD and epilepsy. 
(158-160) 
The scaffolding proteins family (SHANK1, SHANK2, and 
SHANK3) as well as neurexin family (NRXN1 and NRXN3)  
Rare inherited and de novo variants have been documented in the 
ASD.  
(161-166) 
ANDP Novel syndromes associated with ASD such as ASD with facial 
dysmorphism Rare inherited truncating mutations in genes that 
are infrequently mutated in the population 
(167) 
(168, 169) (168, 169). 
FOXP1, MAL and C11orf30 The dysregulation of these genes have been found to be 
implicated in the ASDs pathogenesis as several variants have 
been found to be associated to language delay and autism.  
(168-171) 
AMT, PEX7, SYNE1, VPS13B, PAH, and POMGNT1 Inherited recessive variants in consanguineous families (172) 
noncoding variants in DNAse I hypersensitivity sites located 
within 50 kb 
Variants were  found in consanguineous families (173) 
RELN, PRRT1, ZFP57, TSPAN32/C11orf21, OXTR, EN2, 
MTHFR and MECP2 
• ASD-specific methylation biomarkers 
• Histone acetylation changes i.e. misregulated patterns of 
splicing sites and chromosome remodeling complex 
modifications have been also documented in ASD 
(174-186) 
Non-coding RNA: LncRNA: MSNP1AS, Evf2, RPPH1, NEAT1, 
and MALAT1and MiRNA hsa-miR-21-3p, hsa-miR-29b, hsa-
miR-219-5p, miR-146a, miR-221, miR-654-5p, and miR-656 
miR-133b/miR-206 
LncRNA were found to be more likely involved in the molecular 
function and/or regulation of the specific ASD risk genes 
(172, 187-198) 
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Table 4. Clinical ASD diagnosis methods 
A list of popular global screening tools References 
Modified Checklist for Autism in Toddlers, Revised (M-CHAT) (132, 145-147) 
Autism Diagnostic Interview-Revised (ADI), 
GARS-2: Gilliam Autism Rating Scale-Second Edition (GARS) 
Childhood Autism Rating Scale (CARS) 
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Figure 1. Concurrence of ASD in various syndromes and disorders. 
 
 
